Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 2PROTOCOL AMENDMENT SUMMARY OF CHANGES
DOCUMENT HISTORY
Document Country/countries 
impacted by [CONTACT_125424], version
Amended Clinical Trial Protocol 03  All 13 April 2023, version 1 (electronic 4.0) 
Amended Clinical Trial Protocol 02  All 15 March 2021, version 1 (electronic 3.0)  
Amended Clinical Trial Protocol 01  All 12 March 2020, version 1 (electronic 1.0)  
Original Protocol   09 January 2020, version 2 (electronic 2.0)  
Amended protocol 03 (13 April 2023)
This amended protocol (amendment 03) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.
OVERALL RATIONALE FOR THE AMENDMENT
The main reason for amended protocol [ADDRESS_140931] 
inflammatory biomarker related to structural lung  changes. Therefore, the primary endpoint FEV 1
is proposed to be replaced with the secondary endpoint of FeNO, leading to an overall reduction 
in sample size.
Protocol amendment summary of changes table
Section # and Name [CONTACT_82417] 1.1 Synopsis 
Section 2 Introduction Information from various literature sources for 
FeNO assessment added. 
 The following text is deleted "and 
effect on lung function, airway inflammation 
and the relationship between imaging dynamics 
and FeNO, and the link with asthma control as 
perceived by [CONTACT_102]” To support the rationale for promoting 
FeNO to a primary endpoint. 
The text has been deleted as it is a 
redundant information. 
Section 1.[ADDRESS_140932] inflammation related to structural 
changes in the lung in addition to 
imaging. 
Section 1.1 Synopsis 
Section 3 Objectives and 
Endpoints Minor clarifications on the terminology of the 
primary and secondary functional respi[INVESTIGATOR_125299] (FRI) endpoints.  To more accurately describe the FRI 
endpoints. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 3Section # and Name [CONTACT_82417] 1.[ADDRESS_140933] the shift of this endpoint from 
primary to secondary. 
Section 1.1 Synopsis 
Section 3 Objectives and 
Endpoints Following endpoint has been moved from tertiary/exploratory to secondary and updated as 
follows: 
xChange from baseline to  Week 24 in global 
lung mucus scoring (UCSF mucus scoring) This change is proposed due to the 
increased interest in the assessment of 
presence of mucus plugs in the 
airways. 
Section 1.[ADDRESS_140934] of secondary endpoints was 
simplified and the details will be reported in the 
Statistical Analysis Plan. According to the new template, details 
of testing for secondary endpoints are reported in the Statistical Analysis 
Plan. 
Section 2.3 
Benefit/Risk Assessment The section is updated with the most recent data 
on exposure to dupi[INVESTIGATOR_125300]. To incorporate the most recent 
exposure  data for dupi[INVESTIGATOR_125301]. 
Section 8.1 Efficacy 
Assessments Asthma Control Questionnaire 7-question version 
Details of clinic staff score for FEV 1% predicted 
added. 
Text updated for Asthma Quality of Life 
Questionnaire with Standardized Activities (Self-
Administered) details on overall score calculation. Clarification on clinical staff score for 
FEV 1% predicted. 
 
Clarifications on overall score 
calculation. 
Section 9.1 Statistical 
Hypotheses 
Section 9.2 Sample Size 
Determination and Preservation 
of Type I Error for the Primary 
Endpoints New text added for hypotheses for the updated 
primary endpoints, and simplified testing 
procedure.Use sequential testing for the primary 
endpoints; a ccording to new template, 
details of testing for secondary 
endpoints are reported in the Statistical 
Analysis Plan. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 4Section # and Name [CONTACT_82417] 9.4.1 Efficacy analyses 
Table 7 Efficacy analyses Following sentence is added to the text 
Data may be logarithmically transformed prior to 
analysis if extreme skewness was observed 
based on blinded data review. 
The table for efficacy analyses is updated. The efficacy analyses are updated 
based on changes to the endpoints. 
Section 10.1.7 Data Quality assurance Text for quality tolerance limits is removed. This paragraph is not applicable. 
Throughout the text Following sections are updated 
Section 6.3-Measures to minimize bias: Randomization and Blinding 
Section 8.3-
Adverse events and serious adverse 
events 
Appendix 1 Section 10.1.4-Data protection 
Appendix 1 Section 10.1.6-Dissemination of 
clinical study data and results 
Appendix 1 Section 10.1.9-Study and site start 
and closure 
Appendix 9- Contingency Measures for a regional 
or national emergency that is declared by a 
governmental agency Template related changes 
Throughout the text Minor grammatical, editorial, and/or administrative changes. To improve the readability and/or clarity 
of the protocol. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140935] OF FIGURES................................................................................................................ ..........................9  
1 PROTOCOL SUMMARY ............................................................................................................... 10 
1.1 SYNOPSIS....................................................................................................................... ..............10  
1.2 SCHEMA......................................................................................................................... ...............17  
1.3 SCHEDULE OF ACTIVITIES (SOA)..............................................................................................18  
2 INTRODUCTION................................................................................................................... .........22  
2.1 STUDY RATIONALE................................................................................................................ ......22  
2.2 BACKGROUND ..................................................................................................................... ......23  
2.3 BENEFIT/RISK ASSESSMENT.....................................................................................................24  
3 OBJECTIVES AND ENDPOINTS .................................................................................................28  
3.1 APPROPRIATENESS OF MEASUREMENTS ..............................................................................29  
4 STUDY DESIGN ................................................................................................................... .........30  
4.1 OVERALL DESIGN................................................................................................................. .......30  
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN.........................................................................30  
4.3 JUSTIFICATION FOR DOSE ........................................................................................................3 1 
4.4 END OF STUDY DEFINITION.......................................................................................................3 1 
5 STUDY POPULATION ............................................................................................................... ...32  
5.1 INCLUSION CRITERIA............................................................................................................. .....32  
5.2 EXCLUSION CRITERIA ............................................................................................................. ...33  
5.3 LIFESTYLE CONSIDERATIONS...................................................................................................35  
5.4 SCREEN FAILURES................................................................................................................ ......35  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 65.5 CRITERIA FOR TEMPORARILY DELAYING SCREENING, RANDOMIZATION, OR 
STUDY INTERVENTION ADMINISTRATION ...............................................................................36  
6 STUDY INTERVENTION ............................................................................................................. ..37 
6.1 STUDY INTERVENTION(S) ADMINISTERED..............................................................................37  
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY.......................................................39  
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING .......................................40  
6.4 STUDY INTERVENTION COMPLIANCE ......................................................................................42  
6.5 CONCOMITANT THERAPY ..........................................................................................................42  
6.6 RESCUE MEDICINE................................................................................................................ ......43  
6.7 DOSE MODIFICATION.............................................................................................................. ....43  
6.8 INTERVENTION AFTER THE END OF THE STUDY...................................................................43  
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ...........................................................................................44  
7.1 DISCONTINUATION OF STUDY INTERVENTION .....................................................................44  
7.1.1  Definitive discontinuation ..................................................................................................... ..........44  
7.1.2  Temporary discontinuation...................................................................................................... .......45  
[IP_ADDRESS]  Rechallenge .................................................................................................................... ...............45  
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY..................................[ADDRESS_140936] TO FOLLOW UP .............................................................................................................. ...47  
8 STUDY ASSESSMENTS AND PROCEDURES ...........................................................................48  
8.1 EFFICACY ASSESSMENTS ........................................................................................................48  
8.2 SAFETY ASSESSMENTS ............................................................................................................ 55 
8.2.1  Physical examinations .......................................................................................................... .........55  
8.2.2  Vital signs.................................................................................................................... ...................56  
8.2.3  Electrocardiograms ............................................................................................................. ...........56  
8.2.4  Clinical safety laboratory assessments......................................................................................... .56 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS...........................................................57  
8.3.1  Time period and frequency for collecting AE and SAE information...............................................58  
8.3.2  Method of detecting AEs and SAEs............................................................................................... 58 
8.3.3  Follow-up of AEs and SAEs...................................................................................................... .....58  
8.3.4  Regulatory reporting requirements for SAEs .................................................................................59  
8.3.5  Pregnancy ...................................................................................................................... ................59  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140937] complaints ..................................................................................60  
8.4 TREATMENT OF OVERDOSE......................................................................................................60  
8.5 PHARMACOKINETICS............................................................................................................... ...60  
8.6 PHARMACODYNAMICS ............................................................................................................... 60 
8.7 GENETICS....................................................................................................................... ..............61  
8.8 BIOMARKERS ..................................................................................................................... ..........61  
8.9 MEDICAL RESOURCE UTILIZATION AND HEALTH ECONOMICS ...........................................61  
8.10  USE OF DATA FOR FUTURE RESEARCH..................................................................................61  
9 STATISTICAL CONSIDERATIONS..............................................................................................62  
9.1 STATISTICAL HYPOTHESES.......................................................................................................62  
9.2 SAMPLE SIZE DETERMINATION AND PRESERVATION OF TYPE I ERROR FOR THE 
PRIMARY ENDPOINTS.............................................................................................................. ...62  
9.3 POPULATIONS FOR ANALYSES.................................................................................................63  
9.4 STATISTICAL ANALYSES ........................................................................................................... .63 
9.4.1  Efficacy analyses .............................................................................................................. .............63  
9.4.2  Safety analyses................................................................................................................ ..............65  
9.4.3  Other analyses ................................................................................................................. ..............66  
9.5 INTERIM ANALYSES .............................................................................................................. .....66  
9.5.1  Data Monitoring Committee (DMC)................................................................................................ 66 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ........................67  
10.1  APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS.......67  
10.1.1  Regulatory and ethical considerations .......................................................................................... .67 
10.1.2  Financial disclosure........................................................................................................... .............68  
10.1.3  Informed consent process....................................................................................................... .......68  
10.1.4  Data protection................................................................................................................ ...............69  
10.1.5  Committees structure........................................................................................................... ..........71  
10.1.6  Dissemination of clinical study data and results ............................................................................71  
10.1.7  Data quality assurance ......................................................................................................... .........72  
10.1.8  Source documents ............................................................................................................... ..........72  
10.1.9  Study and site closure......................................................................................................... ...........73  
10.1.10  Publication policy ............................................................................................................. ..............74  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 810.2  APPENDIX 2: CLINICAL LABORATORY TESTS .........................................................................74  
10.3  APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING ................................................75  
10.4  APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY INFORMATION .................................................................................................................... ..........80
 
10.5  APPENDIX 5: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-UP 
ASSESSMENTS ................................................................................................................... ........84  
10.6  APPENDIX 6: LIST OF PROHIBITED LIVE ATTENTUATED VACCINES ...................................85  
10.7  APPENDIX 7: 7-ITEM ASTHMA CONTROL QUESTIONNAIRE (ACQ-7) AND ASTHMA 
QUALITY OF LIFE QUESTIONNAIRE WITH STANDARDISED ACTIVITIES (AQLQ[S])............86  
10.8  APPENDIX 8: COUNTRY SPECIFIC REQUIREMENTS ..............................................................95  
10.9  APPENDIX 9: CONTINGENCY MEASURES FOR A REGIONAL OR NATIONAL 
EMERGENCY THAT IS DECLARED BY A GOVERNMENTAL AGENCY ...................................96  
10.10  APPENDIX 10: RADIATION EXPOSURE .....................................................................................98  
10.11  APPENDIX 11: ABBREVIATIONS ..............................................................................................104  
10.12  APPENDIX 12: PROTOCOL AMENDMENT HISTORY ..............................................................106  
10.12.1  Amended protocol 02 (15 March 2021) .......................................................................................106  
10.12.2  Amended protocol 01 (12 March 2020) .......................................................................................110  
11 REFERENCES..................................................................................................................... ........111  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140938] OF TABLES
Table 1 - Objectives and endpoints................................................................................................ ...............28  
Table 2 - Overview of study interventions administered ............................................................................ ...37  
Table 3 - Low, medium and high daily doses of inhaled corticosteroids (mcg).............................................[ADDRESS_140939] scan and lung 
function assessments........................................................................................................... .........................48  
Table 5 - Clinic staff score for FEV 1% ...........................................................................................................[ADDRESS_140940] resistance ......................................................54  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 101 PROTOCOL SUMMARY
1.1 SYNOPSIS
Protocol title:
Randomized, double blind, placebo controlled study to  evaluate the effect of dupi[INVESTIGATOR_125302], mucus plugging and other lung imaging parameters in patients with asthma
Short title:
VESTIGE
Rationale:
Chronic airway inflammation is a ch aracteristic feature of asthma ( 1). Chronic inflammation is 
associated with mucus production, airway smooth mu scle contraction and hypertrophy, airway 
hyperresponsiveness, and structural airway remodeling ( 2).
Although the pathophysiology of airway remodeling in asthma remains to be fully elucidated, key 
type 2 cytokines are believed to be involved in this process: IL-13 upregulate levels of fractional 
exhaled nitric oxide (FeNO) ( 3), which also affects airway smooth muscle function and mucus 
production, and may influence subepi[INVESTIGATOR_125303]-fibrotic mediators. These effects may contri bute to airway remodeling and obstruction ( 4).
IL-[ADDRESS_140941] ility, and basement membrane thickening ( 5).
Airway remodeling in established asthma is poorly responsive to current therapi[INVESTIGATOR_014], such as 
inhalation of corticosteroids and administration of β2-agonists, anti-leukotrienes, theophylline, 
and biologics ( 6,7). It is plausible that some potentially meaningful airway responses/changes 
involved in airway remodeling could fail to be detected or demonstrated due to the poorsensitivity of the conventional parameters u tilized in these previous clinical studies. 
Patients with normal forced expi[INVESTIGATOR_3741] 1 second (FEV
1) can have regional airway 
structure changes. Functional imaging (FI) is a useful tool for sensitive assessment of structural 
and functional changes in the l ungs after asthma treatment ( 8). According to previous studies 
(8,9,10,11) functional respi[INVESTIGATOR_125304] (FRI) technology has demonstrated a higher 
sensitivity to detect the effect of treatment on lung function than conventional assessments like FEV
1.
Type [ADDRESS_140942] inflammation. Fractional exhaled nitric oxide is a simple, 
non-invasive biomarker that identifies IL-4/[ADDRESS_140943] 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 11remodeling, and increa sed bronchoconstriction ( 12, 13, 14 ). This inflammatory cascade could be 
identified via imaging including reduced airflow and increased airway wall thickness, as well as 
IL-13-mediated goblet cell production. Therefore,  airway structural changes and FeNO levels 
could represent different biomarker components  of IL-4 and IL-13 driven inflammation. FeNO 
has been shown to be a possible predictor of ex acerbation risk and accelerated lung function 
decline and may indicate ongoing damage, although further investigations into this process are 
warranted ( 15, 16, 17, 18, 19, 20 ).
It is hypothesized that the changes in FEV 1observed with dupi[INVESTIGATOR_125305].
The goal of this study is to gain further insight into the effect of dupi[INVESTIGATOR_125306], 
and also explore the effect on airway changes, bi omarkers, and gain preliminary understanding of 
the potential interrelationships between these parameters.
A combination of classical lung function, patient-reported outcome parameters, and FI methods 
has the potential to enhance the descriptio n of the mode of action of new compounds ( 8). In 
addition, results from the recently published AT LANTIS study suggest that a combination of 
biomarkers (FeNO), physiological testing (FEV 1), and imaging approaches provides a
comprehensive assessment of small airway dysfunction (SAD) in asthma ( 21).
The QUEST study ( 22) has shown significant and clinically meaningful effects of dupi[INVESTIGATOR_125307] 1improvement, particularly in the high blood eosinophil count ( ≥300 cells/mm3) population 
at baseline, as early as Week [ADDRESS_140944] inhibition of IL-13 signaling ( 3,4,5).
Therefore, by [CONTACT_125425] s, coupled with clinical outcomes (FEV 1), biomarkers
(FeNO), and patient-reported outcomes (Ast hma Control Questionnaire [ACQ] and Asthma 
Quality of Life Questionnaire with Standardized Activities [AQLQ(S)]), the study is expected to further characterize dupi[INVESTIGATOR_125308] b’s unique mechanism of action (MoA ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140945] volumes detectable by [CONTACT_125426][INVESTIGATOR_125304].  x Proportion of participants achieving FeNO <25 parts per 
billion (ppb) at Week [ADDRESS_140946] volumes corrected for lung volume ([s]iVaw) at total 
lung capacity (TLC) 
Secondary
x To evaluate the effect of dupi[INVESTIGATOR_125309] [ADDRESS_140947] 
wall thickness, ventilation defects and mucus plugging derived from high-
resolution computed tomography (HRCT) 
scans, patient- reported outcomes, FeNO 
and spi[INVESTIGATOR_038].  Efficacy endpoints: 
x Percent change from baseline to Week [ADDRESS_140948] volumes corrected for lung volume ([s]iVaw) at 
functional residual capacity (FRC) 
x Percent change from baseline to  Week [ADDRESS_140949] resistance corrected for lung volume ([s]iRaw) at TLC  
x Percent change from baseline to  Week [ADDRESS_140950] resistance corrected for lung volume ([s]iRaw) at FRC  
x Change from baseline to W eek 24 in global lung lobar 
volumes (iVlobes) at TLC 
x Change from baseline to Week [ADDRESS_140951]-based internal 
airflow distribution (IAD) for each lung zone 
x Change from baseline to W eek 24 in image-based 
ventilation/perfusion (iV/Q) at TLC for each lung zone 
x Change from baseline to Week  24 in global lung mucus 
scoring (UCSF mucus scoring) 
x Change from baseline to Week [ADDRESS_140952]-bronchodilator 
FEV 1 
x Change from baseline to Week 24 in ACQ-7 
x To evaluate safety of dupi[INVESTIGATOR_125310]:  
x Incidence of treatment emergen t adverse events (TEAE) and 
serious adverse events (SAE) including clinically significant 
changes in vital signs and laboratory abnormalities  
x Incidence of adverse events of special interest (AESI) 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 13Objectives Endpoints
Overall design:
APhase [ADDRESS_140953] inflammation through assessments of biomarkers ,
mucu s plugging ,and other lung imaging parameters inparticipants with asthma. 
Disclosure Statement :This is a Parallel Treatment study with 2arms that isblinded for
participants and /orcaregivers and investigators .
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 14Number of participants:
Approximately 97 participants will be randomly assi gned to study intervention, respectively in a 
2:1 ratio for dupi[INVESTIGATOR_12458]: placebo, such that 87 evaluable participants (58 to dupi[INVESTIGATOR_125311] 29 to placebo group) complete the study. Randomi zation will be stratified by [CONTACT_15994] 
(medium/high - no less than 40% in ‘high ICS’ stratum ) of inhaled corticosteroids (ICS) and 
region (Eastern Europe/ROW). In total, no more than 40% participants should be in "Eastern Europe" strata.
Intervention groups and duration:
Study participation for each participant will be  a total of minimum 29 weeks and up to 41 weeks.
The study includes 3 study periods:
xScreening period: 4 weeks (±1 week), from signed informed consent to randomization.
xRandomized, placebo-controlled treatment period: 24 weeks from baseline (Day 1).
xPost treatment follow-up period: up to 12 weeks or until the participants switch to 
commercialized dupi[INVESTIGATOR_12458] (or other biologic products), whatever comes first.
Participants who fulfill the inclusion criteria and do not meet any of the exclusion criteria will be 
randomized (2:1) to one of the following investigational medicinal products (IMP).
xDupi[INVESTIGATOR_12458]: participants will receive a load ing dose of 600 mg of dupi[INVESTIGATOR_12458] (2 x 300 mg 
dupi[INVESTIGATOR_125312] 1, followed by 300 mg every 2 weeks (Q2W) for 24 weeks.
xPlacebo: participants will receive 2 x 2 mL placebo injections SC on Day 1, then 1 placebo 
injection Q2W for 24 weeks.
Study intervention(s)
Investigational medicinal product(s)
Dupi[INVESTIGATOR_125313].
Dupi[INVESTIGATOR_12458] 300 mg:
xFormulation: A 150 mg/mL dupi[INVESTIGATOR_125314] a prefilled syringe to deliver 300 mg in 
a 2 mL injection.
xRoute of administration: SC injection.
xDose regimen: Q2W after an initial loading dose of 600 mg (2 injections of 300 mg) on 
Day 1.
Matching Placebo:
xFormulation: Matching placebo will be supplie d as an identical formulation to the active 
formulation without dupi[INVESTIGATOR_12458], in a prefilled syringe to deliver placebo in a 2 mLinjection.
xRoute of administration: SC injection.
xDose regimen: Q2W after an initial loading dose (2 injections) on Day 1.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 15Posttrial access to study medication :Posttrial access to study medication will be assessed in
accordance tothe country requirements and the legislation in place .
Statistical considerations :
xSample size calculations and preservation of Type I error for the two primary 
endpoints
To control the type -I error rate for the 2primary endpoints, a hierarchical testing 
procedure will be applied at a 2 -sided 5% significance level, ie ,each hypothesis will be 
formally tested o nly if the preceding one is significant at 5% level. The hierarchy of the 
tests for primary endpoints will be:
a)Proportion of participants achieving response of FeNO <25 ppb at Week 24
b)Percentage change from baseline to Week 24 in untrimmed distal [s]iVaw a t TLC
 
xPrimary analysis:
For the primary endpoint proportion of participants achieving FeNO <25 pbb at Week 24, 
the analysis will beconducted by [CONTACT_125427] -Mantel -Haenszel (CMH) test adjusted by 
[CONTACT_81473]. Comparison of the proportions of responders between dupi[INVESTIGATOR_125315], and corresponding odds ratios and 95% CI along with the p -value 
will be reported .For participants who discontinued the study treatment, off -treatment data 
will be used to determine the responder/non -responder status. Missing data at Week 24 
will be considered as non -responders.
Percent change from baseline to Week 24 in distal [s]iVa w at TLC will be analyzed using 
amixed model repeated measures model (MMRM ). The model will include percent 
change from baseline values up to Week 24 as the response variable, and treatment group, 
region ( Eastern Europe/ROW ), ICS dose level (medium/high) , visit, treatment -by-visit 
interaction, baseline value, and baseline -by-visit interaction as covariates .An unstructured 
covarianc e matrix will be used to model the within participants errors. No imputations for 
missing values will be carried out. The least square (LS) mean of each treatment group, the 
LS mean difference between the dupi[INVESTIGATOR_125316], and the corresponding 
95% CI of the differences and p -values will be provided. For participants who
discontinued the study treatment, off -treatment imaging data , as available , will be included 
in the analysis. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 16xAnalysis of secondary endpoints:
Secondary endpoints relating to change or percen t change from baseline will be analyzed
with MMRM model in a manner similar to that for the primary imaging endpoint.
xMultiplicity considerations for the secondary endpoints:
A multiplicity control procedure and the selected list of seconda ry endpoints to be tested in 
the hierarchical order will be specified in the Statistical Analysis Plan. Regardless of eligibility to be declared significant, results for all comparisons will be presented. Descriptive statistics including number of pa rticipants, mean, standard deviation, and LS 
means will also be provided.
Safety analyses : All safety variables will be summarized using descriptive statistics.
Data Monitoring Committee: No
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 171.2 SCHEMA
Figure 1 - Graphical study design
 
ACQ-7= 7-item Asthma Control Questionnaire;  AQLQ(S) =Asthma Quality of Life Questionna ire with Standardized Activities; D=Day; FeNO= Fractional exhaled nitric oxide; FU= Follow-up; HRCT= High-resolution 
computed tomography; ICF=Informed Consent Form; mg=milligram; ml=milliliter; Q2W= every 2 weeks; R=Randomization; V=Visit  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 20aParticipants who prematurely disco ntinue the study intervention (prior to com pleting the 24-week treatm ent period) should atten d an Early Treatment Discontinuation (ETD) vi sit at earliest convenience with all the 
assessments planned for the End of Treatment visit (V5), except HRCT scans and IMP. In particular cases when the ETD visit is c losed to a regular study vi sit, ETD could be merged and will replace the regular 
visit. In addition, the participants will be asked and encouraged  to complete all the remaining st udy visits according to the v isit schedule until and incl uding the EOT visit (V5). Unde r exceptional circumstances 
when a participant cannot come to the site for the scheduled visit, a phone cont act can be made after sponsor approval is given . During the phone contac t, at least information about AEs and concomitant 
medication should be collected. 
bParticipants who prematurely disco ntinue the study should attend an  Early Study Discontinuation ( ESD) visit at earliest conveni ence with all the procedures planned for the End of Treatment Visit (Visit 5) except 
IMP. If the Investigator considers that the time from the last HRCT scan exposure is not acceptable, the investigation will not  be done. 
cPost-treatment Follow-up: up to 12 Week s or until the partici pants switch to commercialized du pi[INVESTIGATOR_12458] (or other biologic produc ts), whatever comes first.  
dVisit 6 will be a telephone vi sit. For the participants who switch to commerci alized dupi[INVESTIGATOR_12458] (or other biologic products), th e call visit should be done prior to the firs t injection with commercialized dupi[INVESTIGATOR_12458] (or 
other biologic products). 
eVital signs, including bloo d pressure (mmHg), heart rate (beats per minute), respi[INVESTIGATOR_697] (breaths per minute), body temper ature (degrees Celsius).  
fA complete physical examination will include, at a minimum, ass essments of the cardiovascular, respi[INVESTIGATOR_696], gastrointestinal an d neurological systems and will be performed at V1, V2 and V5. Body weight (kg) will 
be measured at V1, V2 an d V5. Height (cm) will be  measured only at V1. 
gReversibility test: Three attempts may be pe rformed during the screening period to meet the qualifying criteria for reversibili ty before randomization. This is only required if a revers ibility test meeting eligibility 
criterion was not performed within 6 months prior to Visit 1. 
hAsthma Control Questionnaire-7 (ACQ-7): it ems 1 to 6 should be  completed by [CONTACT_2299], ind ependently from their physician , the study nurse or any other medical pe rsonnel and without any help from friends 
or relatives. The questionnaire should be completed by [CONTACT_125428]/ or clinical tests, in a qui et place. ACQ-5 scores (mean of the respon ses to the first 5 questions) and ACQ-6 
(mean of the responses to the first 6 questions) will be derived from ACQ-7. The local values of FEV [ADDRESS_140954] atistical analysis we will use centrally read values. 
iAsthma Quality of Life Question naire with Standardized Activi ties [AQLQ(S)] should be completed  by [CONTACT_2299], independent ly from their physician, the study nurse or  any other medical personnel and without 
any help from friends or relatives. The qu estionnaire should be complet ed by [CONTACT_125429]/or cl inical tests, in a quiet place. 
jFeNO should be conducted prior to spi[INVESTIGATOR_125317] ≥[ADDRESS_140955] will be performed after a wash out period of bronchodilators 
according to their action du ration as detailed in Table 4 (Section  8.1). Retesting of FeNO can be done one additi onal time during screening if the eligibil ity criterion for FeNO was not met at V1. FeNO will be re-
checked at randomization visit (V2) for eligibility. Further det ails on the procedure for measuring FeNO will be provided in a separate instruction manual  
kCentrally read. Scans are respi[INVESTIGATOR_125318] e, as per scans protocol. Further detai ls on the HRCT scan will be  provided in a separate instruction manual. The wash out 
time of the asthma controll ers and rescue medication before HRCT and lung function assessments is detailed in Table 4  (Section  8.1). If HRCT scan cannot be performed at D1  due to logistic reasons, it can be 
scheduled the next day. In this particular situation the investigator should ensure th at the IMP loading do se is administered a fter the HRCT scan, at D1+[ADDRESS_140956]-BD FEV1 or after (in the latter case  the wash-out period of SABA should be ensured), as per Investiga tor's decision. 
lFOT should be conducted prior to spi[INVESTIGATOR_038]. Further details on  FOT will be provided in a separate instruction manual. 
mCentrally read. Spi[INVESTIGATOR_125319] P administration, in the morning if  possible, but if testing can o nly be done at another time  during the day, then the testing should be done at 
approximately the same time of day at each  visit throughout the study. Spi[INVESTIGATOR_038] w ill be performed after a wash out period of bronchodilators according  to their action duration as detailed in Table 4 (Section  8.1). 
This will be verified before performing th e measurements. A participant who is unable to complete a successful spi[INVESTIGATOR_125320] t as defined by [CONTACT_125430]-BD FEV1 at V1 can be retested one additional time during  the screening period . For spi[INVESTIGATOR_125321] 1 local values from V1 and V2 
before randomization (the results from central reading will not be  available on the same day). Th e recommendation is to perform  the FeNO and FOT before spi[INVESTIGATOR_125322] (Vis it 1) and urine pregnancy tests at the ot her visits using dips tick. A negative resu lt must be obtained at Visits [ADDRESS_140957] will  be performed at home at the end of follow-up visit.  
oRetesting of eosinophil count is allowed up to three times during  the screening period to meet inclusion criteria for showing e osinophil count ≥300 cells/microliter (cells/mL) (I 06) be fore randomization. This is only 
required if the participant does not have the blood eosinophil count measur ed within 6 months prior to  V1 in the ab sence of OCS  treatment.  
pHepatitis screening covering hepati tis B surface antigen (HBs Ag), total hepatitis B core  antibody (total HB cAb) including IgM HBcAb; hepatitis C virus antibodies (HCVAb ). In case of results showing HBsAg 
(negative) and HBcAb (positive), HBV DNA testing will be performe d to rule out a false positivi ty or to clarify the serological  status if the Investigator finds it unclear to interpret in absence of known HBV infection. 
In case of results showing HCVAb (positive), HCV RNA testing ma y be performed to rule out a fals e positivity. Human Immunodefic iency Virus (HIV) screening (Ant i-HIV-1 and HIV-2 antibodies). 
q Tuberculosis (TB) testing would only be performed on a country by  [CONTACT_125431]. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140958] investigational (home dosing diary) and non-investigational product (as thma background therapy diary) information.  Recorded data will be collected by [CONTACT_125432]. 
sInvestigational product administrations (Q2W) should be separated by [CONTACT_2669] 11 days. The adminis tration is performed on site during planned visits alter nating with Q2W home ad ministration (participant, 
caregiver, or health care professional) or in a health care fac ility. At D1, loading dose dupi[INVESTIGATOR_125323] 600 mg (300 mg x 2 syri nges/injections); [ADDRESS_140959]  scan (D1 +1 Day).  
NOTE: 
x The contingency measures for a regional or national emergency declared by a government al agency are detail ed in Appendix 9 ( Section  10.9).  
x In case of severe asthma exacerbations treated with systemic corticosteroids, the visits can be postponed up to 1 week to ensur e the wash-out period (Table 4) is co mpleted before performing HRCT scan, 
FeNO, FOT, and spi[INVESTIGATOR_038]. In case this is not possible (eg, a participant experiences an exacer bation shortly be fore the sched uled visit), the procedures  can be performed as plan ned, but it should be 
recorded that the participant had rece ntly taken systemic corticosteroids. 
 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140960] inflammation ( 1).
Type [ADDRESS_140961] type 2 immune responses are me diated by [CONTACT_125433]-4, IL-5, and 
IL-13, which occur in approximately 50% of patients with asthma ( 10).
Dupi[INVESTIGATOR_24783] a fully human anti-IL- [ADDRESS_140962] demonstrated its efficacy in 
moderate-to-severe asthma patients by [CONTACT_125434], 
improving the lung function and asthma control ( 22) as well as reducing oral glucocorticoid use 
(23).
Dupi[INVESTIGATOR_125324]-to-severe asthma in the United 
States, and for the treatment of patients with severe asthma in Europe and Japan.
2.[ADDRESS_140963] inflammation is a ch aracteristic feature of asthma ( 1). Chronic inflammation is 
associated with mucus production, airway smooth muscle contraction and hypertrophy, airway
hyperresponsiveness, and structural airway remodeling ( 2).
Although the pathophysiology of airway remodeling in asthma remains to be fully elucidated, key 
type 2 cytokines are believed to be involved in this process: IL-13 upregulate levels of fractional 
exhaled nitric oxide (FeNO) ( 3), which also affects airway smooth muscle function and mucus 
production, and may influence subepi[INVESTIGATOR_125303]-fibrotic mediators. These effects may contri bute to airway remodeling and obstruction ( 4).
IL-[ADDRESS_140964] on mucus secretion, smooth muscle contra ctility, and basement membrane thickening ( 5).
Airway remodeling in established asthma is poorly responsive to current therapi[INVESTIGATOR_014], such as 
inhalation of corticosteroids and administration of β2-agonists, anti-leukotrienes, theophylline,
and biologics ( 6,7). It is plausible that some potentially meaningful airway responses/changes 
involved in airway remodeling could fail to be detected or demonstrated due to the poorsensitivity of the conventional parameters util ized in these previously clinical studies. 
Patients with normal forced expi[INVESTIGATOR_3741] 1 second (FEV
1) can have regional airway 
structure changes. Functional imaging is a useful tool for sensitive assessment of structural and 
functional changes in the lungs after asthma treatment ( 8). According to previous studies ( 8,9,10,
11) functional respi[INVESTIGATOR_125304] (FRI) technology  has demonstrated a higher sensitivity to
detect the effect of treatment on lung function than conventional assessments like FEV 1.
Type [ADDRESS_140965] inflammation. Fractional exhaled nitric oxide is a simple, 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 23non-invasive biomarker that identifies IL-4/[ADDRESS_140966] 
remodeling, and increa sed bronchoconstriction ( 12, 13, 14 ). This inflammatory cascade could be 
identified via imaging including reduced airflow and increased airway wall thickness, as well as 
IL-13-mediated goblet cell production. Therefore,  airway structural changes and FeNO levels 
could represent different biomarker components  of IL-4 and IL-13 driven inflammation. FeNO 
has been shown to be a possible predictor of ex acerbation risk and accelerated lung function 
decline and may indicate ongoing damage, although further investigations into this process are 
warranted ( 15, 16, 17, 18, 19, 20 ).
It is hypothesized that the changes in FEV 1observed with dupi[INVESTIGATOR_125325] d changes in airway volumes detectable by 
[CONTACT_125435][INVESTIGATOR_125304].
The goal of this study is to gain further insight into the effect of dupi[INVESTIGATOR_125306], 
and also explore the effect on airway changes, bi omarkers, and gain preliminary understanding of 
the potential interrelationships between these parameters.
A combination of classical lung function, pati ent-reported outcome parameters, and FI methods
has the potential to enhance the descriptio n of the mode of action of new compounds ( 8). In 
addition, results from the recently published AT LANTIS study suggest that a combination of 
biomarkers (FeNO), physiological testing (FEV 1), and imaging approaches provides a 
comprehensive assessment of small airway dysfunction (SAD) in asthma ( 21).
The QUEST study ( 22) has shown significant and clinically meaningful effect of dupi[INVESTIGATOR_125326] 1improvement , particularly in the high blood eosinophil count ( ≥300 cells/mm3) population 
at baseline, as early as Week [ADDRESS_140967] inhibition of IL-4 and IL-13 signaling 
(3,4,5).
Therefore by [CONTACT_125436],  coupled with clinical outcomes (FEV 1), biomarkers 
(FeNO), and patient-reported outcomes [ACQ, and AQLQ(S)], the study is expected to further 
characterize dupi[INVESTIGATOR_12458] ’s unique mechanism of action (MoA).
2.2 BACKGROUND
Dupi[INVESTIGATOR_24783] a fully human monoclonal antibody produced by [CONTACT_125437] (DNA) technology in Chinese Hamster Ovary cell suspension culture. It inhibits IL-4 and IL-13 signaling by [CONTACT_125438]- 4Rα subunit of the IL -4 and IL-13 receptor 
complexes. 
The results of the conducted studies of dupi[INVESTIGATOR_125327], with trea tment compared to placebo, in lung function 
parameters such as FEV
1.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140968] 3 decades ( 24). However, FRI emerges as a 
novel technique that can simulate different outco mes such as ventilation, lung deposition, and 
perfusion of airway blood vessels ( 10).
Functional respi[INVESTIGATOR_125328] [ADDRESS_140969] resistance ( 8,25,26).
Although not yet demonstrated, dupi[INVESTIGATOR_125329] a positive 
effect on mucus plugging. Functional respi[INVESTIGATOR_125330] n-acetyl cysteine ( 27).
In addition to a reduction in inflammation in th e larger airways, dupi[INVESTIGATOR_125331]. Previous studies have suggested that regional 
hyperinflation appears to be a sensitive marker for small airways inflammation ( 9, 11 ,28).
Functional respi[INVESTIGATOR_125332] (lobar) levels of hyperinflation by [CONTACT_125439] (where values >115% are judged to be hyper inflated compared to a reference level).
Another parameter that can be derived from FRI is the image-based ventilation/perfusion ratio 
(iV/Q) ( 29). As the main function of the lung is to transfer oxygen, anti-inflammatory properties 
of dupi[INVESTIGATOR_125333] a reduc tion of inflammation in the larger airways of 
asthmatics as well as the small airways from the atmosphere into the blood; therefore, the iV/Q parameter is highly relevant from a pathophysiological and clinical perspective.
Previous studies did demonstrate that both FEV
1and FRI based biomarkers of airway volume 
(iVaw) and resistance (iRaw) can evaluate th e effects of treatment in asthma and chronic 
obstructive pulmonary disease (COPD). This study is designed to assess the effect of dupi[INVESTIGATOR_125334], airway inflammation and the re lationship between imaging dynamics and FeNO.
2.3 BENEFIT/RISK ASSESSMENT
Dupi[INVESTIGATOR_125335] ( ≥12 years) in
over 60 countries worldwide and review for this i ndication is ongoing in several other countries 
worldwide. In the US, dupi[INVESTIGATOR_125336]-on maintenance treatment of adults and pediatric patients aged 6 years and olde r with moderate-to-severe asthma characterized 
by [CONTACT_125440] (OCS) dependent asthma; in the EU as 
an add-on maintenance treatment for adult and adoles cent (12 years and older) patients as well as 
in children 6 to 11 years old with severe asthma with type 2 inflammation characterized by [CONTACT_125441]/or raised FeNO who are inadequately control led with appropriate 
combination therapy (high-dose ICS over 12 years or age, medium-to-high dose ICS in those younger) plus another medicinal product for maintenance treatment. In Japan, dupi[INVESTIGATOR_125337] (aged ≥12 years) with severe or refractory bronchial 
asthma.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 25Dupi[INVESTIGATOR_125338] 60 c ountries worldwide, including US, EU, and Japan, 
for the treatment of adults with AD, in over 60 countries for use in adolescent patients ( ≥12 years) 
with atopic dermatitis (AD) and in over 50 countries for use in pediatric patients (age 6-11 years) 
with AD. In the US and Europe dupi[INVESTIGATOR_125339] 6 months to 5 years of age.
In addition, dupi[INVESTIGATOR_125340] 50 countries worldwide, as an add-on maintenance 
treatment for the treatment of adults in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Dupi[INVESTIGATOR_125341], 
aged 12 years and older, with eosinophilic esophagitis (EoE), and for the treatment of adult patients with prurigo nodularis (PN).
This study in patients with asthma aims to gain insight into the effect of dupi[INVESTIGATOR_125342]. Th e combination of clinical outcomes (FEV
1),
Asthma Control Questionnaire (ACQ), forced oscillometry (FOT), biomarkers (FeNO) and functional imaging will provide further charac terization of dupi[INVESTIGATOR_12458]’s unique mechanism of 
action (MoA). The study is medically and scientifically justified. The imaging study is designed to fulfill an unmet need by [CONTACT_125442][INVESTIGATOR_125343], and if the aims are achieved, it will help HCPs 
understanding dupi[INVESTIGATOR_12458]'s MoA, therefore supporting optimal therapeutic management.
The functional imaging will be performed using HRCTs which will provide scientifically useful 
information on bronchodynamics and hyperinflation, airway resistance, airway wall thickness, 
ventilation defects, mucus plugging that cannot be obtained with another method. 
The protocol entails that each participant will re ceive [ADDRESS_140970] scans (at D1, W4 and W24), each 
comprised by 2 acquisitions, respectively on fu ll inspi[INVESTIGATOR_1516] (total lung capacity) and end 
expi[INVESTIGATOR_1516] (functional residual capacity) utilizing respi[INVESTIGATOR_125344]. Therefore, each participant
will be exposed to a total of [ADDRESS_140971] scanner (at le ast 64 slices with radiation reduction options) is 
approximately 1.[ADDRESS_140972] acquisitions  per participant, the average cumulative 
dose per participant will be approximately 10.8 mSv ( 30,31,32,33).
The natural background radiation exposure form natural sources is approximately 3.[ADDRESS_140973] are exclusively stochastic effects, primarily cancer
induction, given that current diagnostic doses of less than 10 mSv are well below the threshold for deterministic effects, which generally start at 2000 mSv (2 Gy) ( 2,3).
The estimated additional relative risk of all ca ncers from the International Commission of 
Radiologic Protection published in 2007 ( 2) is 0.005% per each mSv of radiation dose. This is a 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 26very small number in comparison with the baseline  incidence of all cancers, which is orders of 
magnitude higher (it is estimated that the lifetime ri sk of developi[INVESTIGATOR_125345] 
30%). Therefore, the radiation risk of a single chest CT performed with dose-reduction techniques is considered negligible.
Based on the [LOCATION_006] Health Protection Agency classi fication of health risks related to radiation 
exposure, the proposed study falls into the “low risk” category, which implies 1 in 10 000–[ADDRESS_140974] acquisition in this research protocol do 
not outweigh the benefits of dupi[INVESTIGATOR_24736].
For further information on radiation exposure, please refer to Appendix 9 ( Section 10.9 ).
Dupi[INVESTIGATOR_125346] (loading dose of 600 mg of 
dupi[INVESTIGATOR_12458] (2x 300 mg dupi[INVESTIGATOR_125347]) on Day 1, followed by 300 mg every 2 weeks (Q2W) which demonstrated positive benefit/risk ( 22,34,35).
No tissue targets or specific hazards to humans were identified in nonclinical general and 
reproductive toxicology studies.
As of 28 September 2022, overall approximately, 14 056 participants were enrolled in the 
development program for dupi[INVESTIGATOR_125348]: 564 as healthy volunteers, 5009 from AD studies (including hand and foot dermatitis), 468 from eosinophilic esophagitis studies, 275 from allergy (grass and pea nut) studies, 59 from the bullous pemphigoid 
study, 51 from the allergic bronchopulmonary aspergillosis study and 7630 from asthma, 
CRSwNP, chronic rhinosinusitis without nasal pol yposis, allergic fungal rhinosinusitis, COPD,
PN, chronic spontaneous urticaria, chronic inducib le cold urticaria and chronic pruritis of 
unknown origin studies.
Based on the available sales figures and World He alth Organization define d daily dose of 21.4 mg 
for parenteral formulations, the cumulative patient exposure in ma rketed experience is estimated 
to be 926 369 patient years from 01 March 2017 through 30 September 2022, including 220 161 patient years during the interval period from 01 April 2022 through 30 September 2022.The adverse drug reactions identified to date  for dupi[INVESTIGATOR_125349], 
conjunctivitis (including allergic and bacterial), oral herpes, herpes simplex, blepharitis, dry eye, eye pruritus, keratitis, ulcerative keratitis, eosinophilia, enterobiasis and anaphylactic reaction, 
angioedema, serum sickness and arthralgia. Thes e adverse drug reactions occur with relatively 
low frequency with dupi[INVESTIGATOR_24736], and were  generally mild or moderate, transient, and 
manageable. More significant serious allergic reactions were very rare. Importantly, no increased overall infection risk was observed in patients treated with dupi[INVESTIGATOR_12458]. 
Systemic hypersensitivity has been established as an important identified risk with dupi[INVESTIGATOR_12458]. As 
protein therapeutics, all monoclonal antibodies are potentially immunogenic. Rare serious and systemic hypersensitivity reactions have been observed in the dupi[INVESTIGATOR_125350]/serum sickness-like reaction in th e adult AD program and anaphylaxis related to 
dupi[INVESTIGATOR_125351].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 27An important potential risk for dupi[INVESTIGATOR_24783] “eosinophilia associated with clinical symptoms in 
asthma patients”. The observed increase in eosinophi l count is transient, which is consistent with 
the current understanding of the mechanism of action of dupi[INVESTIGATOR_12458]. In dupi[INVESTIGATOR_125352], a small number of patients with asthma experien ced serious systemic eosinophilia presenting with 
clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, conditions which are often treated with systemic corticosteroid therapy. These events have been seen in other drug development programs for severe asthma and 
usually, but not always, have been associated with the reduction of OCS therapy suggesting possible unmasking of these conditions with tapering of corticosteroids during dupi[INVESTIGATOR_81228]. The association of dupi[INVESTIGATOR_125353]. Health care providers should be alert to eosinophilia associated with vasculitic rash, worsening of pulmonary symptoms, pulmonary infiltrate, cardiac complications, and/or neuropathy presenting in their 
patients, especially upon reduction of systemic corticosteroids.
Patients with known helminth infections were ex cluded from participation in clinical studies, 
therefore it is not known if dupi[INVESTIGATOR_125354] i nfluence the immune response against helminth 
infections. Consequently, patients with pre-existing helminth infecti ons should be treated for their 
helminth infection before initiating therapy with dupi[INVESTIGATOR_12458].
The safety data available to date, in conjunction w ith the risk monitoring and mitigation strategies 
in the study protocol, and the clinical benefit of dupi[INVESTIGATOR_125355] 2approved indications (AD, asthma, CRSwNP) s upport a favorable benefit-risk profile for 
dupi[INVESTIGATOR_12458].
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of dupi[INVESTIGATOR_125356]’s Brochure ( IB) and 
its updates.
Benefit/risk assessment related to COVID-19The Sponsor recognizes that the coronavirus di sease 2019 (COVID-19) pandemic is having an 
impact on the conduct of clinical trials. The Sponsor is monitoring the situation closely and may suspend study screening activities until the impact of the COVID-[ADDRESS_140975] at study level, all the contingency measures are described in Appendix 9(Section 10.9 ). The participants will be properly informed on all these options by [CONTACT_125443], as mentioned in the Informed Consent 
Form. Implementation of such mechanisms may diff er country by [CONTACT_1606], depending on country 
regulations and local business continuity plans.
Based on the aforementioned potential benefits to  patients participating in LPS15834, and the
appropriate precautions and mitigations institut ed to manage any potential impact of COVID-[ADDRESS_140976] of the trial and the safety of the patients, the Sponsor assesses that the overallbenefit-risk balance is positive for the conduc t of and patient participation in this trial.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140977] volumes detectable by [CONTACT_125426][INVESTIGATOR_125304].  x Proportion of participants achieving FeNO <25 parts per billion 
(ppb) at Week [ADDRESS_140978] volumes corrected for lung volume ([s]iVaw) at total 
lung capacity (TLC) 
 
Secondary
x To evaluate the effect of dupi[INVESTIGATOR_125309] [ADDRESS_140979] 
wall thickness, ventilation defects and 
mucus plugging derived from high-
resolution computed tomography (HRCT) 
scans, patient- reported outcomes, FeNO 
and spi[INVESTIGATOR_038].  Efficacy endpoints: 
x Percent change from baseline to Week [ADDRESS_140980] volumes corrected for lung volume ([s]iVaw) at 
functional residual capacity (FRC) 
x Percent change from baseline to  Week [ADDRESS_140981] resistance corrected for lung volume ([s]iRaw) at TLC 
x Percent change from baseline to  Week [ADDRESS_140982] resistance corrected for lung volume ([s]iRaw) at FRC 
x Change from baseline to W eek 24 in global lung lobar 
volumes (iVlobes) at TLC 
x Change from baseline to Week  [ADDRESS_140983]-based internal 
airflow distribution (IAD) for each lung zone 
x Change from baseline to W eek 24 in image-based 
ventilation/perfusion (iV/Q) at TLC for each lung zone 
x Change from baseline to W eek 24 in global lung mucus 
scoring (UCSF mucus scoring) 
x Change from baseline to Week [ADDRESS_140984]-bronchodilator FEV 1 
x Change from baseline to Week 24 in ACQ-7 
x To evaluate safety of dupi[INVESTIGATOR_125357]:  
x Incidence of treatment emergent adverse events (TEAE) and 
serious adverse events (SAE) including clinically significant 
changes in vital signs and laboratory abnormalities  
x Incidence of adverse events of special interest (AESI) 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 29Objectives Endpoints
3.1 APPROPRIATENESS OF M EASUREMENTS
The efficacy and exploratory assessments will be done using imaging results (HRCT) , coupled 
with clinical outcomes (FEV 1),patient -reported outcomes [ACQ and AQLQ (S)],biomarkers 
(FeNO) and forced oscillation technique (FOT ).The HRCT scans , spi[INVESTIGATOR_038] , and FOT 
assessment swillbe performed using central reading .
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140985] inflammation through assessments of biomarkers, mucus plugging, and ot her lung imaging parameters in participants
with asthma.
Study participation for each participant will be  a total of minimum 29 weeks and up to 41 weeks.
The study includes 3 study periods:
xScreening period: 4 weeks (±1 week), from signed informed consent to randomization.
xRandomized, placebo-controlled treatment period: 24 weeks from baseline (Day 1).
xPost treatment follow-up period: up to 12 weeks or until the participants switch to 
commercialized dupi[INVESTIGATOR_12458] (or other biologic products), whatever comes first.
Participants who fulfill the inclusion criteria and do not meet any of the exclusion criteria will be 
randomized (2:1) to one of the following investigational medicinal products (IMP).
xDupi[INVESTIGATOR_12458]: participants will receive a load ing dose of 600 mg of dupi[INVESTIGATOR_12458] (2 x 300 mg 
dupi[INVESTIGATOR_125312] 1, followed by 300 mg every 2 weeks (Q2W) for 24 weeks.
xPlacebo: participants will receive [ADDRESS_140986] acebo injections SC on Day 1, then 1 placebo 
injection Q2W for 24 weeks.
Randomization will be stratified by [CONTACT_125444] (medium/high- no less than 40% in ‘high ICS’ 
stratum) and region (Eastern Europe/ROW). In total, no more than 40% participants should be in 
"Eastern Europe" strata.
Study intervention discontinuation follow-up
Participants who prematurely discontinue the study intervention (prior to completing the 24-week
treatment period) should attend an Early Treatmen t Discontinuation (ETD) visit at the earliest 
convenience with all the assessments planned for the End of Treatment (EOT) visit (V5), except 
HRCT and IMP. In particular cases when the ETD visit is close to a regular study visit, ETD could be merged and will replace the regular visit (See Section 7.1.1 ).
In addition, the participants will be asked and encouraged to complete all the remaining study 
visits according to the visit schedule until and including the EOT visit (V5).
4.[ADDRESS_140987] appropriate design to investigate 
the objectives of this study. A randomization ratio of 2:1 for the active tr eatment versus placebo 
was incorporated into the study design in order to limit the number of participants exposed to placebo.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 314.3 JUSTIFICATION FOR DOSE
The dose regimen of SC dupi[INVESTIGATOR_125358] 300 mg Q2W. Participants will 
receive an initial loading dose of 600 mg (2 x 300 mg) dupi[INVESTIGATOR_125359] 1, and Q2W dosing will commence [ADDRESS_140988].  
Proof of concept has been established in the ACT11457 study ( 34) with [ADDRESS_140989] 300 cells/ μL or a sputum eosinophil level of at least 3%, partially controlled or 
uncontrolled by [INVESTIGATOR_49377]-to-high doses of ICS plus long- acting β2 agonists (LABA
(fluticasone/salmeterol, budesonide/formoterol, or mometasone/formoterol) were randomized to 
the study. The study showed significant efficacy in a population of mostly severe asthmatics with 
poor asthma control and decreased lung function with mostly high doses of ICS in combination with a LABA.
The results from the Phase 2b dose ranging study (DRI12544) ( 35) showed that [ADDRESS_140990] of the efficacy 
endpoints. Both doses were safe and well tolerate d with a profile comparable to that seen with 
placebo except for an increased number of injecti on site reactions. To further characterize the 
optimal regimen for patients, both regimens were assessed in the Phase 3 study (QUEST) ( 22),
which confirmed the findings from previous studies, showing comparable efficacy and safety
profile in both [ADDRESS_140991] approved dose (300 mg) has been selected.
4.[ADDRESS_140992] completed th e study if he/she has completed all phases of the 
study including the post treatment follow-up visit (V6).
The end of the study is defined as the date of the last visit of the last participant in the study.
For the participants who permanently discontinue  the planned treatment, the recommended 
follow-up is described in Section 4.1 .
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 325 STUDY POPULATION
Selection criteria are in line with the approved  indication and refer to labeling information. 
Contraindications, precautions of use and warnings were considered.
Prospective approval of protocol deviations to rec ruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.
5.1 INCLUSION CRITERIA
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
I 01. 18 to 70 years of age inclusive with the diagnosis of asthma based on Global Strategy for 
Asthma Management and Prevention (GINA) 2019 ( 1) at the time of signing the informed 
consent.
Type of participant and disease characteristicsI 02. History of ≥1 exacerbation (s) in the previous year before V1.
Exacerbation is defined as deterioration of asth ma that results in emergency treatment, 
hospi[INVESTIGATOR_96648], or treatment with systemic steroids.
I 03. Uncontrolled moderate-to-severe asthma (ACQ- 5 ≥1.5)at V1 and V2, prior to
randomization.
I 04. Pre-bronchodilator FEV
1≤80% of predicted normal at V1 and V2, prior to randomization.
I 05. Exhibit bronchodilator reversibility ( ≥12% and [ADDRESS_140993] SABA 
administration) during screening, prior to randomization.
I 06. Blood eosinophil ≥300 cells / μLand Fe NO ≥25 ppb during screening and prior to 
randomization.
NOTES:
- Historical values of blood eosinophil count meeting the eligibility criterion measured 
within 6 months prior to SV1 in the absence of OCS treatment are allowed. 
- FeNO value to be checked for eligibility at V2 as well.
I 07. Existing treatment with medium to high dose ICS in combination with a second controller 
(eg, LABA, LTRA) ± a third controller. The dose regimen should be stable ≥1month prior 
V1 and during screening.
I 08. Willing and able to comply with all clinic visits and study related procedures.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140994] dose of study intervention or until the participants switch to 
commercialized dupi[INVESTIGATOR_12458] (or other biologic pro ducts), whatever comes first, as described in 
Section 10.4 (Appendix 4).
Male participants are eligible to participate if they agree to contracept ion conditions described in
Section 10.4 (Appendix 4) during the intervention period and up to [ADDRESS_140995] dose of 
study intervention or until the participants switch to commercialized dupi[INVESTIGATOR_12458] (or other biologic products), whatever comes first.
Informed ConsentI 10. Capable of giving signed informed consent as described in Appendix 1 ( Section 10.1 )
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.
5.2 EXCLUSION CRITERIA
Participants are excluded from the study if any of the following criteria apply:
Medical conditions 
E 01. Current smoker (cigarette or e-cigarette) or cessation of smoking within 1 year prior to
randomization.
E 02. Previous smoker with a smoking history >[ADDRESS_140996] who experiences an asthma exacerba tion (defined as a deterioration of asthma 
that results in emergency treatment, hospi[INVESTIGATOR_125360], or treatment with 
systemic steroids) during screening.
E 05. Current acute bronchospasm or status asthmaticus.E 06. Diagnosed pulmonary (other than asthma) or systemic disease associated with elevated 
peripheral eosinophil counts.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_140997] that the participant has been adequate ly treated and the treatment with a biologic 
agent can be initiated, in the medical judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing would only be performed on a country by [CONTACT_125445] e local guidelines if required by [CONTACT_125446].
E 08. History or clinical evidence of COPD including Asthma-COPD Overlap Syndrome 
(ACOS) or any other significant lung diseas e (eg, lung fibrosis, sarcoidosis, interstitial 
lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome).
E 09. History or current evidence of clinically significant disease in any non-respi[INVESTIGATOR_2133] 
(eg, cardiovascular, hepatic, nervous system, gastrointestinal, endocrinological, 
rheumatological, dermatological), which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
E 10. Current evidence of clinically significant oncological disease, which in the opi[INVESTIGATOR_125361].
E 11. Participants with any of the following results at V1:
- Positive (or indeterminate) hepati tis B surface antigen (HBsAg) or,
- Positive IgM hepatitis B core antibody (HBcAb) or,- Positive total HBcAb confirmed by [CONTACT_125447],- Positive hepatitis C virus antibody (HCVAb) confirmed by [CONTACT_125448].
E 12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at V1.
Prior/concomitant therapy E 13. Any biologic therapy (including experimental treatments and dupi[INVESTIGATOR_12458]) or any other 
biologic therapy/immunosuppressant within 3 months prior to V1.
E 14. Treatment with live (attenuated) vaccine within [ADDRESS_140998] vaccination with live, attenuated vaccines planned during the 
course of the study (based on national vaccination schedule/local guidelines), it will be determined, after consultation with a physicia n, whether the administration of vaccine can 
be postponed until after the end of the study, or preponed to before the start of the study 
without compromising the health of the participant:
- Participants for whom administration of li ve (attenuated) vaccine can be safely 
postponed would be eligible to enroll into the study.
- Participants who have their vaccination prepon ed can enroll in the study only after a 
gap of 4 weeks following administration of the vaccine.
E 15. Treatment with oral corticosteroids  (OCS) within [ADDRESS_140999].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 35E 17. Treatment with an investigational drug with in 1 month or within 5 half-lives (if known), 
whichever is longer, prior to V1.
Diagnostic assessments E 18. Suspected or high risk of parasitic infect ion (helminthic infection), unless clinical and (if 
necessary) laboratory assessments have ruled out active infection prior to randomization.
Other exclusions E 19. Females who are lactating, breastfeeding, or who are pregnant.E 20. Individuals accommodated in an instituti on because of regulatory or legal order; prisoners 
or subjects who are legally institutionalized.
E 21. Participants are dependent on the Sponsor or Investigator (in conjunction with Section 1.61 
of the International Council for Harmonisation [ICH] Good Clinical Practice [GCP]Ordinance E6).
E 22. Participants are employees of the clinical stud y site or other individuals directly involved 
in the conduct of the study, or immediate family members of such individuals.
E 23. Sensitivity to any of the study interventions, or components thereof, or drug or other 
allergy that, in the opi[INVESTIGATOR_125362], contraindicates participation in the study.
E 24. Any country-related specific regulation that  would prevent the subject from entering the
study.
5.3 LIFESTYLE CONSIDERATIONS
No restrictions are required.
5.4 SCREEN FAILURES
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently eligible to be randomized. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publis hing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any SAE.
Reasons for screen failure may be unfulfilled elig ibility criteria and withdrawal of consent during 
screening period, between screening and randomization.
Participants who do not meet the eligibility criteria for participation in this study and for whom 
resolution of the screen failure reason may not be expected within a reasonable time frame, will 
be deemed as screen failure. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 36Rescreening: The participants may be rescreened once during the open screening period and all 
the screening procedures will be repeated; a di fferent participant identification number will be 
issued.
There is no requirement for a waiting period betwee n the screen failure date and the rescreening
date. The Interactive voice recognition system  (IVRS)/ Interactive web response system (IWRS)
report will flag rescreened participants. Participants that are rescreened must sign a new consent form and all Visit [ADDRESS_141000] be repeated.
Retesting: If certain dynamic laboratory tests do not meet the eligibility criteria, these laboratory 
assessments may be repeated, at the discretion of the Investigator, if it is judged that they are
likely to return to acceptable range for study inclusion within the screening visit window (21 to 
35 days) prior to Day 1. These participants do not need to sign a new ICF and a new participant
number will not be allocated.
Retesting of eosinophil values is allowed up to  3 times during the screening period to meet
inclusion criteria for showing eosino phil count ≥300 cells/ μL(I 06) before randomization. This is 
only required if the participant does not have the blood eosinophils measured within 6 months prior to V1 in the absence of OCS treatment.
A participant who is unable to complete a successful spi[INVESTIGATOR_125363] (ATS) criteria or assessed by [CONTACT_125449]-BD FEV1 at V1 can be retested [ADDRESS_141001] meeting the eligibility 
criterion was not performed within 6 months prior to V1.
FeNO can be assessed one additional time during sc reening period if FeNO value measured at V1 
does not meet the eligibility criterion.
5.5 CRITERIA FOR TEMPORARILY DELAYING SCREENING, RANDOMIZATION, OR 
STUDY INTERVENTION ADMINISTRATION
During a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated pr ocedures, contingency measures proposed in 
Appendix 9 ( Section 10.9 ) should be considered for the screening, randomization, or 
administration of study intervention.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 376 STUDY INTERVENTION
Study intervention is defined as any investigati onal intervention(s), marke ted product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study protocol.
6.1 STUDY INTERVENTION(S) ADMINISTERED
Table 2 - Overview of study interventions administered
Intervention name [CONTACT_125502][INVESTIGATOR_125364]/Vaccine Other 
Dose formulation solution solution 
Unit dose strength(s) 150 mg/mL Not applicable 
Dosage level(s) Loading dose of 600 mg at Day 1a 
following 300 mg Q2W injections 2 x 2 mL placebo injections at Day 1 following 
Q2W injections 
Route of administrationbSC injection SC injection 
IMP and NIMP IMP IMP 
Packaging and labeling  One glass prefilled syringe packed in a 
participant kit box. Both glass prefilled 
syringe and box will be labeled as 
required per country requirement.  One glass prefilled syringe packed in a 
participant kit box. Both glass prefilled syringe and box will be labeled as required 
per country requirement. 
aIf HRCT scan cannot be performed at D1 due to logistic reasons, it can be scheduled the next day. In this  particular situation the investigator 
should ensure that the IMP loading dose is ad ministered after the HRCT scan, at D1+1 day. 
bA subcutaneous injection si tes should alternate betw een the upper thighs, 4 quadrants of th e abdomen or the upper arms, so that  the same site 
is not injected twice during consecutive ad ministrations. Injection in the upper arms can only be done by a trained person (car egiver) trained by 
[CONTACT_125450]. 
Investigational medicinal product(s)
Dupi[INVESTIGATOR_125313].
The IMP is administered every 14±3 days (Q2W) during the 24-week treatment period.Dupi[INVESTIGATOR_12458] 300 mg
xFormulation: a 150 mg/mL dupi[INVESTIGATOR_125314] a prefilled glass syringe to deliver 
300 mg in a 2 mL injection.
xRoute of administration: SC injection.
xDose regimen: Q2W after an initial loading dose of 600 mg (2 injections of 300 mg) on 
Day 1.
Matching Placebo 
xFormulation: matching placebo will be supplied  as an identical formulation to the active 
formulation without dupi[INVESTIGATOR_12458], in a prefilled syringe to deliver placebo in a 2 mLinjection.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 38xRoute of administration: SC injection.
xDose regimen: Q2W after an initial loading dose (2 injections) on Day 1.
In specific situations, between the protocol-scheduled on-site visits, interim visits may be required 
for IMP dispensing. As an alternative to the on-site IMP dispensing, IMP may be supplied from the site to the participant via a Sponsor-approved courier company where allowed by [CONTACT_125451].
For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site acc ess, contingency measures are included in 
Appendix 9 ( Section 10.9 ).
Investigational medicinal product will be administ ered by [CONTACT_737]/health care professional 
or designee following clinical procedures and bloo d collection. Participants should be monitored 
for at least 30 minutes after admi nistration of all IMP injections at site. The monitoring period 
may be extended as per country-specific or local site-specific requirements.
Subcutaneous injection sites should alternate between the upper thighs, 4 quadrants of the 
abdomen or the upper arms, so that the same si te is not injected twice during consecutive 
administrations. Injection in the upper arms can on ly be done by a trained person (caregiver) or
health care professional but not by [CONTACT_125452].
The Investigator or delegate will train the particip ant (or caregiver) how to prepare and inject IMP 
at Visit [ADDRESS_141002] dose 
of the 2 injections at D1. The participant (or ca regiver) will perform the second injection under 
the supervision of the Investigator or delegate. This training must be documented in the 
participant ’s study file. Participant or caregiver should be trained by [CONTACT_125453]-monitor/monitor at home for 
at least 30 minutes (or longer per country specif ic or local site-specific requirements) following 
injection. In case of hypersensitivity symptoms, the participant should contact [CONTACT_125454]/emergency.
Participants should be instructed to avoid miss ing any dose of medication during the study. Any 
participant who misses one dose should be reminded to be diligent, in order to avoid further 
missing doses thereafter. In case of missed dose(s), no loading dose of [ADDRESS_141003] (dupi[INVESTIGATOR_24885]) 
will be administrated at home by [CONTACT_125455]/herself or by a caregiver or by a nurse or 
at the study site. A home dosing diary for collecting  information related to at home injections will 
be provided. The home dosing diary will be kept as source data in the participant ’s study file. 
Non-investigational medicinal product(s)
Participants should be on a stable dose of medium to high dose ICS in combination with a second 
controller medication (eg, LABA, LTRA, theophylline ) ≥1 month prior to V1 and during the 
Screening Period ( Table 3 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141004] controller for their as thma will be considered eligible for this study,
also at a stable dose ≥1 month prior to V1 and during the Screening Period.
xFormulation and route(s) of administration: refer to label.
xDose regimen: As prescribed.
The asthma background therapy should be maintained on a stable dose during the study treatment 
period.
Short- acting β2 agonists (SABA ) may be used as rescue medication during the study if needed.
Systemic corticosteroids are allowed for the tr eatment of severe asthma exacerbations.
Table 3 - Low, medium and high daily doses of inhaled corticosteroids (mcg)
Inhaled corticosteroid Low Medium High
Beclometasone dipropi[INVESTIGATOR_16847] (CFC) 200-500 >500-1000 >1000 
Beclometasone dipropi[INVESTIGATOR_16847] (HFA) 100-200 >200-400 >400 
Budesonide (DPI) 200-400 >400-800 >800 
Ciclesonide (HFA) 80-160 >160-320 >320 
Fluticasone furoate (DPI) 100 n.a. 200 
Fluticasone propi[INVESTIGATOR_16847] (DPI) 100-250 >250-500 >500 
Fluticasone propi[INVESTIGATOR_16847] (HFA) 100-250 >250-500 >500 
Mometasone furoate 110-220 >220-440 >440 
Triamcinolone acetonide 400-1000 >1000-2000 >2000 
CFC= Chlorofluorocarbon propellant; DPI=Dry powder  inhaler; HFA= Hydrof luoroalkane propellant 
The GINA table above refers to metered doses. This is not a table of equivalence, but an
estimated clinical comparability, based on availa ble studies and product information. Categories 
of “low”, “medium” and “high’ doses are base d on published information and available studies, 
including direct comparisons where available. Doses may be count ry-specific depending on 
labeling requirements. For new preparations, manufacturer’s  information should be reviewed 
carefully, products containing the same molecule may not be clinical equivalent (1).The list 
presents examples of ICS and might support future changes.
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY
Investigators or other authorized persons (eg, pharmacists) are responsible for storing the IMP in a 
secure and safe place in accordance with local regulations, labeling specifications, policies, and 
procedures.
Control of IMP storage conditions, especially cont rol of temperature (eg, refrigerated storage) and 
information on in-use stability and instructions  for handling the [COMPANY_011] compound must be 
managed according to the rules provided by [CONTACT_125456].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 40The expi[INVESTIGATOR_125365] (when required by [CONTACT_125457]), and 
storage conditions are written on the IMP labels.
1. The Investigator or designee must confirm ap propriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention.
2. Only participants enrolled in the study may receive study intervention and only authorized 
site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlle d, and monitored (manua l or automated) area 
in accordance with the labeled storage conditions with access limited to the Investigatorand authorized site staff.
3. The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountabilit y, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).
4. Further guidance and information for the final disposition of used and unused study
interventions are provided in a Pharmacy manual.
Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_320],  etc) must be promptly notified to the Sponsor.
Some deficiencies may be recorded through a complaint procedure (see Section 8.3.6 ).
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by [CONTACT_429]. In this case, the Investigator will be responsible for promptly addressing any request made by [CONTACT_1034], in order to recall the IMP and eliminate potential hazards.
Under no circumstances will the Investigator supply IMP to a third party, allow the IMP to be 
used other than as directed by [CONTACT_13129], or dispose of IMP in any other manner.
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING
Randomization
A randomized treatment kit number list will be generated centrally by [CONTACT_13225]. The IMP
(dupi[INVESTIGATOR_24885]) will be packaged in accordance with this list. 
The [COMPANY_011] Clinical Supplies team will provide th e randomized treatment kit number list and the 
Study Biostatistician will provide the randomiz ation scheme to the centralized treatment 
allocation system. This centralized treatment allocation system will generate the participant
randomization list according to which it will allocate the treatments to the participants.
The Investigator obtains treatment kit numbers at randomization (V2) and subsequent scheduled 
visits via an Interactive Voice Response System/Interactive Web Response System (IVRS/IWRS) that will be available 24 hours a day.  
Participants who meet the entry criteria will be  randomized to receive either dupi[INVESTIGATOR_125366]. Participants will be randomized using a 2:1 randomization ratio for dupi[INVESTIGATOR_12458] 300 mg 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 41Q2W and placebo Q2W. Randomization will be stratified by [CONTACT_125444] (medium and high-
no less than 40% in ‘high ICS’ stratum ) and region (Eastern Europe/ROW). In total, no more than 
40% participants should be in "Eastern Europe" strata.
A randomized participant is defined as a participant who is registered and assigned with a 
treatment kit number from the centralized treatment allocation system, as documented from its log file. A participant cannot be randomiz ed more than once in the study.
Returned IMP from the participant ’s home should not be re-dispensed to the participants.
BlindingDupi[INVESTIGATOR_125367] [ADDRESS_141005] the blind, each treatment kit of 2 mL (dupi[INVESTIGATOR_71763]/placebo) glass prefilled syringes will be 
prepared such that the treatments (dupi[INVESTIGATOR_125368]) are identical and indistinguishable and will be labeled with a tr eatment kit number. The randomized treatment kit 
number list will be generated by [CONTACT_13225].
Both the participant and Investigator will be bl inded to assigned active drug or placebo. Study 
participants, investigators, and study site pers onnel will not have access to the randomization 
(treatment codes).
Randomization code breaking during the studyIn case of an AE, the code must only be broken in circumstances when knowledge of the IMP is 
required for treating the participant.
Code breaking can be performed at any time by [CONTACT_125458]/IWRS 
and/or by [CONTACT_125459]. If the blind is broken, the Investigator must document the date, time of day, and reason for code breaking.
Participant withdrawal will only occur when the code  break call is made at the site level, not the
study level. This means that if the Emergency Unblinding transaction is performed by [CONTACT_737] (ie, at the site level), then the participant will be withdrawn from treatment. However, if the Emergency Unblinding transaction is perf ormed by [CONTACT_125460] (ie, at the 
study level, as the Global Safety Officer is not site based), then the participant will not be 
withdrawn from treatment. Sponsor safety staff may unblind the intervention assignment for any 
participant with an SAE for the purpose of expedited regulatory reporting (see Section 8.3.2 ).
Sponsor staff involved in the conduct of the stud y will remain blinded to the participant 
intervention assignment.
Participants who are withdrawn from treatment should be encouraged to remain in the study and 
the Investigator should discuss with them the key visits to attend (see Section 7.1.1 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 426.4 STUDY INTERVENTION COMPLIANCE
Measures taken to ensure and document treatment compliance and IMP accountability include:
xProper recording of treatment kit number as required on appropriate electronic case report 
form (e-CRF page for accounting purposes.
xAll medication treatment kits (whether empty or unused) are returned by [CONTACT_125461] a treatment dispensing is planned:
- The completed home dosing diary (returned to the site at each visit), returned treatment 
kit boxes and any unused prefilled syringes will be used for drug accountability purposes. 
xThe Investigator or designee tracks treatmen t accountability/compliance, either by [CONTACT_125462], or by [CONTACT_125463]. 
The monitor in charge of the study then checks the data entered on the IMP administration page 
by [CONTACT_125464]. 
The Investigator or pharmacist will also keep accurate records of the quantities of the IMP
received, dispensed, used, unused, and returned/destroyed. The product accountability andinventory form/system are to be updated each time IMP is dispensed.
All used, partially used, or unused treatments will  be destroyed at each respective site, after
accountability and reconciliation have been performed. The site must not destroy the unused IMP unless the Sponsor provides written authorization. Confirmation of destruction will be provided to the Sponsor.
6.5 CONCOMITANT THERAPY
Any medication or vaccine (including over-the -counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:
xReason for use.
xDates of administration including start and end dates.
xDosage information including dose and frequency.
Prohibited concomitant therapy: 
xAny biologic therapy (including experimental treatments and dupi[INVESTIGATOR_12458]) or any other 
biologic therapy/immunosuppressant.
xTreatment with live (attenuated) vaccine.
xTreatment with systemic corticosteroids (systemic corticosteroids can only be used to treat 
an asthma exacerbation, and are not allowed to be used for other conditions)
During the FU period the asthma treatment will be administered based on Investigator's medical 
judgment and normal clinical practice.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141006],
the measurements should be performed af ter a wash-out time mentioned in Table 4 (Section 8.1 ).
In case of severe asthma exacerbations treated wi th systemic corticosteroids, the visits can be 
postponed up to 1 week to ensure the wash-out pe riod (Table 4) is completed before performing 
HRCT scan, FeNO, FOT, and spi[INVESTIGATOR_038]. In case this is not possible (eg, a participantexperiences an exacerbation shortly before the sc heduled visit), the procedures can be performed 
as planned, but it should be recorded that the participant had recently taken systemic 
corticosteroids. The date and time of rescue medication administra tion as well as the name [CONTACT_125503].
6.7 DOSE MODIFICATION
Not applicable.
6.8 INTERVENTION AFTER THE END OF THE STUDY
Not applicable.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 447 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL
Withdrawal of consent for treatment (ie, treatment  discontinuation at participant request) should 
be distinguished from (additional) withdrawal of consent for follow-up visits. The site should 
document any case of withdrawal of consent.
7.1 DISCONTINUATION OF STUDY INTERVENTION
7.1.1 Definitive discontinuation
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued, the participant will remain in the 
study to be evaluated for safety and efficacy. See the schedule of activities (SoA) for data to be 
collected at the time of disc ontinuation of study intervention ( Section 1.3 ).
Discontinuation of study intervention for abnorm al liver function should be considered by [CONTACT_13134] a participant meets one of the conditions outlined in the algorithm Increased inalanine aminotransferase (ALT) ( Section 10.5 ) or if the Investigator believes that it is in best 
interest of the participant.
List of criteria for permanent disc ontinuation of study intervention
Every effort should be made to document the reason(s) for discontinuation of study intervention 
and this should be documented in the e-CRF.
Participants may be withdrawn from the study intervention for the following reasons:
xAt their own request or at the request of their legally authorized representative (legally
authorized representative means an individual or judicial or other body authorized underapplicable law to consent on behalf of a prospective participant to the participant 's 
participation in the procedure(s) involved in the research).
xIf, in the Investigator's opi[INVESTIGATOR_1649], continuation in the study would be detrimental to the
participant 's well-being.
xAt the specific request of the Sponsor.
xIf the Emergency Unblinding transaction is performed by [CONTACT_737] (ie, at the site 
level).
xPregnancy.
xAnaphylactic reactions or systemic allergic re actions that are related to IMP and require 
treatment.
xAny opportunistic infection, such as tuberculosis or other infections whose nature or 
course may suggest an immunocompromised status.
xSerum ALT >3 upper limit of normal (ULN) and Total Bilirubin >[ADDRESS_141007] 
(seeSection 10.5 , Appendix 5).
xSerum ALT >[ADDRESS_141008] if baseline ALT ≤[ADDRESS_141009] or ALT >[ADDRESS_141010] if baseline ALT >[ADDRESS_141011] 
(see Section 10.5 , Appendix 5). “Baseline” refers to ALT sampled at baseline visit or, if 
baseline value is unavailable, to the la test ALT value before the baseline visit.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 45See the SoA ( Section 1.3 ) for data to be collected at the ti me of intervention discontinuation and 
follow-up and for any further evaluations that need to be completed.
Any abnormal laboratory value will be immediately  rechecked for confirmation before making a 
decision of definitive discontinuation of  the IMP for the concerned participant.
Handling of participants after perman ent study intervention discontinuation :
Participants who prematurely discontinue the study intervention (prior to completing the 
24-weeks treatment period) should attend an ETD visit at earliest convenience with all procedures 
required at the EOT visit, except HRCT and IMP. In  particular cases when the ETD visit is closed 
to a regular study visit, ETD could be merged a nd will replace the regular visit. In addition, the 
participants will be asked and encouraged to comp lete all the remaining study visits according to 
the visit schedule until and including the EO T visit (V5). Participants will be followed-up
according to the study procedures specified in this protocol in SoA ( Section 1.3 ). Under 
exceptional circumstances when a participant cannot come to the site for the scheduled visit, a 
phone contact [CONTACT_125465]. During the phone contact, at least 
information about AEs and concomitant medication should be collected. 
All cases of permanent discontinuation of stud y intervention should be recorded by [CONTACT_125466] e-CRF when considered as confirmed.
7.1.2 Temporary discontinuation
Temporary intervention discontinuation may be considered by [CONTACT_13136] a regional or national emergency declared 
by a governmental agency. For a regional or national emergency declared by a governmental 
agency, contingency measures are included in Appendix 9 ( Section 10.9 ). For all temporary 
intervention discontinuations, duration should be re corded by [CONTACT_125467] e-CRF.
In addition, the following conditions will be ca uses for temporary discontinuation of study 
intervention:
xInfections or infestations that do not respond to medical treatment.
xTreatment with a live (attenuated) vaccine.
xTreatment with immunomodulating biologics (including experimental treatments).
xTreatment with systemic corticosteroids (excep t systemic corticosteroids used to treat an
asthma exacerbation) or systemic immunosuppressive drugs.
xAny laboratory abnormality that meets temporary  treatment discontinuation criteria as per 
Appendix 5 ( Section 10.5 ).
[IP_ADDRESS] Rechallenge
Reinitiation of intervention with the IMP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator will have  considered according to his/her best medical 
judgment that the responsibility of the IMP in the occurrence of the concerned event was unlikely and if the selection criteria for the study are still met (refer to Section 5.1 and Section 5.2 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 46For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 9 ( Section 10.9 ).
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY
xA participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. T his is expected to be uncommon.
xParticipants who prematurely discontinue the study, should attend an Early Study 
Discontinuation (ESD) visit at the earliest c onvenience with all the procedures planned for 
the End of Treatment Visit (Visit 5) except IMP, as shown in the SoA ( Section 1.3 ). See 
SoA for data to be collected at the time of study discontinuation and follow-up and for any 
further evaluations that need to be completed. If the Investigator considers that the time 
from the last HRCT scan exposure is not acceptable, the investigation will not be done.
xThe participant will be permanently discont inued both from the study intervention and 
from the study at that time.
xIf the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collec ted before such a withdrawal of consent.
xIf a participant withdraws from the study, he /she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records.
If participants no longer wish to take the IMP, they will be encouraged to remain in the study.The investigators should discuss with them key visits to attend. The value of all their study data 
collected during their continued involvement will  be emphasized as important to the public health 
value of the study.
Participants who withdraw from the study inte rvention should be explicitly asked about the 
contribution of possible AEs to their decision, and any adverse event (AE) information elicited 
must be documented.
All study withdrawals should be recorded by [CONTACT_3433] e Investigator in the appropriate screens of the 
e-CRF and in the participant ’s medical records. In the medica l record, at least the date of the 
withdrawal and the reason should be documented.
In addition, a participant may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention should be di stinguished from withdrawal of consent for 
follow-up visits and from withdrawal of consent for non-participant contact [CONTACT_6492]-up,
eg, medical record checks. The site should document any case of withdrawal of consent.
Participants who have withdrawn  from the study cannot be rerandomized/reallocated (treated) in 
the study. Their inclusion and intervention numbers must not be reused.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141012] be taken if a participan t fails to return to the clinic for a required study 
visit:
xThe site must attempt to contact [CONTACT_125468]/or should continue in the study.
xBefore a participant is deemed lost to follow-up, the Investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if 
necessary, a certified letter to the partic ipant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_14386] s hould be documented in the participant’s 
medical record.
xShould the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1
(Section 10.1.9 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 488 STUDY ASSESSMENTS AND PROCEDURES
xStudy procedures and their timing are summarized in the SoA ( Section 1.3 ). Protocol 
waivers or exemptions are not allowed.
xAdherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
xAll screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. Th e Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
xProcedures conducted as part of the participant’s routine clinical management (eg, blood
eosinophil count, reversibility test) and obtained before signing of the ICF may be utilized 
for screening purposes provided the procedures met the protocol-specified criteria and 
were performed within the time frame defined in the SoA.
xThe lab tests will be done by [CONTACT_125469], the maximum amount of blood 
collected from each participant over the dura tion of the study will be according to the 
routine clinical practice in each country and site . As the blood analysis will be performed 
by [CONTACT_125469], any leftover blood sample will not be used for any other research purposes related to the study (re-analyses) or for future exploratory use (secondary use).Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.
xFor a regional or national emergency declared by a governmental agency, contingency 
measures are included in Appendix 9 ( Section 10.9 ).
8.1 EFFICACY ASSESSMENTS
Disease-specific efficacy measures
Spi[INVESTIGATOR_038]
A spi[INVESTIGATOR_125369](ATS)/European Respi[INVESTIGATOR_3764] 
(ERS) recommendations will be used. Spi[INVESTIGATOR_125370] ( 36).
For pre-bronchodilator measured parameters, including FEV 1and FVC spi[INVESTIGATOR_125371]:
Table [ADDRESS_141013] scan and lung 
function assessments
Oral Xanthine derivatives 
Long-acting beta agonists (LABA) (eg, salmeterol) [ADDRESS_141014](LAMA) (eg, Tiotropi[INVESTIGATOR_1890]) 48 hours 
Inhaled ICS 12 hours 
Inhaled ICS/LABA  24 hours 
Inhaled Ultralong ICS/LA BA combinations     48 hours 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 49Inhaled and/or nebulized SABAs (eg, salbutamol) 6 hours 
Inhaled and/or nebulized SA MAs (eg, ipratropi[INVESTIGATOR_1890])  8 hours 
SABA/SAMA combination 8 hours 
Inhaled and/or nebulized corticosteroid (ICS) 12 hours 
Long-acting beta agonists (LABA)   [ADDRESS_141015] (LAMA)  48 hours 
Inhaled ICS/LABA 24 hours 
Systemic corticosteroids (oral, IM, IV) [ADDRESS_141016] scan, FeNO, FOT and 
spi[INVESTIGATOR_038]. In case this is not possible (eg, a participant experiences an exacerbation shortly 
before the scheduled visit), the procedures can be performed as planned, but it should be recorded
that the participant had recently taken systemic corticosteroids.  
For post-bronchodilator FEV 1, the measurement should follow the steps as that at screening test 
for reversibility validation. 
At all visits, spi[INVESTIGATOR_125372], in the morning, if
possible. The same spi[INVESTIGATOR_125373], including calibration, will be 
used to perform spi[INVESTIGATOR_125374], whenever possible, the same person should perform the measurements; afternoon/evening is allowable in  the exceptional circumstance when morning 
spi[INVESTIGATOR_125375]; spi[INVESTIGATOR_125376].
Pulmonary function tests will be measured in the sitting position; however, if necessary to 
undertake the testing with the subject standing or in another position, this should be noted on the spi[INVESTIGATOR_125377]. For any subject, the position should be consistent throughout the study. 
Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained 
at every visit. The acceptability criteria must  be applied before the repeatability criteria. 
Unacceptable maneuvers must be discarded befor e applying the repeatability criteria. At least 
[ADDRESS_141017] be calibrated following the principles of the ATS/ERS guidelines every day 
that a study subject is seen, and spi[INVESTIGATOR_125378]. The calibration records should be kept in a reviewable log. It is preferred that the calibrat ion equipment (ie, 3-liter syringe) that is used to 
calibrate the spi[INVESTIGATOR_125379] a vali dated calibration according to the manufacturer’s 
specifications. A participant who is unable to complete  a successful spi[INVESTIGATOR_125380]-BD FEV
1at V1 can be retested one additional time during the screening period of the study. The 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141018] been withheld for the appropriat e intervals. Subjects will receive 2 to up to 
4 puffs of albuterol/salbutamol from a primed metered dose inhaler (MDI). Alternatively, and only if it is consistent with usual office prac tice (to be documented), reversibility may be 
performed using inhalation of nebulized albuterol/s albutamol. Spi[INVESTIGATOR_125381] 30 minutes after administration of br onchodilator. Reversibility, which is defined as 
an increase in absolute FEV
1of 12% over the baseline value, with an absolute increase of at least 
[ADDRESS_141019] meeting 
eligibility criterion was not performed within 6 months prior to V1.
Asthma Control Questionnaire 7-question version
The ACQ-7 is comprised of 7 items: the first [ADDRESS_141020] common asthma symptoms: 
1. frequency in past week awoken by [CONTACT_125470]; 2. severity of asthma symptoms in the morning; 3. limitation of daily activities due to asthma; 4. shortness of breath due to asthma;and 5. wheeze; plus question 6. short-a cting bronchodilator use; and 7. FEV
1(% predicted).
Participants are asked to recall how their asth ma has been during the previous week and to 
respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum 
impairment).
Clinic staff score for FEV 1% is predicted on a 7-point scale. The details are given in Table 5.
Table 5 - Clinic staff score for FEV 1%
FEV 1% predicted Score
>95% predicted 0 
95%-90% 1 
89%-80% 2 
79%-70% 3 
69%-60% 4 
59%-50% 5 
<50% 6 
Abbreviation: FEV 1 = forced expi[INVESTIGATOR_3741] 1 second 
A global score is calculated: the questions are equally weighted and the ACQ-7 score is the mean 
of the 7 questions and, therefore, between 0 (tot ally controlled) and 6 (severely uncontrolled). 
Higher score indicates lower asthma control . Participants with a score below 1.[ADDRESS_141021] inadequately 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141022] change that can be considered clinically important, corresponding to the Minimal Clinically Important Difference (MCID) defined by [CONTACT_125471].
The participants will complete the ACQ-[ADDRESS_141023].
The ACQ-5 (Mean of the responses to the first 5 questions) and ACQ-6 (Mean of the responses to 
the first 6 questions) will be derived from ACQ-7. For the ACQ-7 scores will be considered the 
local values of FEV
1For the statistical analysis we will use the centrally read values.
Asthma Quality of Life Questionnaire with Standardized Activities (Self-Administered)Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ[S]) was designed as a 
self-administered patient-reported outcome to meas ure the functional impairments that are most 
troublesome to adolescents ≥12 years of age and adults as a result of their asthma. The instrument 
is comprised of 32 items, each rated on a 7-poi nt Likert scales from 1 to 7. The AQLQ(S) has 
4 domains. The domains and the number of items in each domain are as follows:
xSymptoms (12 items).
xActivity limitation (11 items).
xEmotional function (5 items).
xEnvironmental Stimuli (4 items).
Individual items are equally weighted. The overall score is the mean of response to each of the 
32 questions (ranging from 1 to 7). Higher scores  indicate better quality of life. The instrument 
has been used in many clinical trials, and it has been shown to be reliable, valid (participant
interviews), and sensitive to change. The MCID for AQLQ(S) is 0.5 ( 37).
The participants will complete the AQLQ(S) on paper.
Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ[S]) should be 
completed by [CONTACT_2299], independently from their physician, the study nurse or any other 
medical personnel and without any help from friends or relatives. The questionnaire should be completed by [CONTACT_125472], including spi[INVESTIGATOR_038], in a 
quiet place.
Forced Oscillometry
Asthma is an inflammatory airway disease affecting the entire bronchial tree, including the small 
airways, defined as those with an internal dia meter of [ADDRESS_141024] that, within subjects with asthma, the small airways are dysfunctional ( 38), inflamed ( 39),
and damaged ( 40), therefore playing an important role in asthma. Forced oscillation technique 
(FOT) R5  - R20 is a direct measure of anatomical narrowing in the small airways ( 41). The FOT
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141025]: maintenance of 
an airtight seal of the lips around a mouthpi[INVESTIGATOR_125382] e and breathing normally through the measuring 
system with a nose-clip occluding the nares. FOT should be conducted prior to spi[INVESTIGATOR_038]. The 
assessment will be done by [CONTACT_18014]. Further details on the procedure will be provided in a 
separate instruction manual.
Fractional Exhaled Nitric OxideFractional exhaled nitric oxide will be analyzed using a NIOX instrument using a flow rate of 
50 mL/s and reported in ppb. This assessment sh ould be conducted prior to spi[INVESTIGATOR_125383] [ADDRESS_141026] will be performed after a wash out period of bronchodilators according to their action duration as detailed in Table 4 (Section 8.1 ). Retesting of FeNO can be done  one additional time during 
screening if the eligibility criterion for FeNO was not met at V1. FeNO will be re-checked at randomization visit (V2) for eligibility. Further details on the procedure for measuring exhaled nitric oxide with NIOX will be provided in a separate instruction manual. FeNO assessment will 
be performed by [CONTACT_125473]. T he recommendation is to perform the investigations in the 
following order: FeNO, FOT, spi[INVESTIGATOR_038].
Functional Respi[INVESTIGATOR_125384] a non-invasive measurement of the participant specific 
respi[INVESTIGATOR_2133]. A set of distinct imaging para meters analyzes exposure, structure and function 
of the lungs and airways in asthma. 
The process starts with the acquisition of low dose, pre-bronchodilator HRCT scans of the 
participant.
The measurements are performed on the segmented 3-dimensional geometries from these scans. 
Computational fluid dynamics (CFD) is used to quantify airflow and exposure.
Airway Volume ([s]iVaw)
(s)iVaw is the change of volume of the airways (in mL), taking into account the lung volume 
changes (in L) as well. 
With anti-inflammatory compounds, often the lung volumes reduce (they become less inflamed), 
while the airway volumes increase, since lower vo lume increase airway resistance showing a 
better pi[INVESTIGATOR_125385].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141027] volumes ([s]iVaw).
Airway caliber changes are more sensitive compared to FEV 1hence can provide additional 
insights into potential remodeling and a dditional improvements not described by [CONTACT_10266] 1
(eg, between Weeks 4 and 24).
A study to evaluate the use of FI to visualize and quantify airways involvement in asthma and 
COPD evaluated the correlation between FEV 1and FRI-based airway volumes, showing that a 
10% change in FEV 1corresponds to a change of 21% in airway volumes ( Figure 2 )(Lanclus et al. 
Respi[INVESTIGATOR_125386]) , indicating that FRI is a more sensitive tool to detect therapeutic effects 
compared to FEV 1.
Figure [ADDRESS_141028] Resistance ([s]iRaw)
(s)iRaw is defined as the pressure drop over the fl ow rate of the fluid. The unit is [kPa/(L/s)]) or
[kPa*s/L]. 
Asthmatic lungs have higher regional resi stances due to presence of mucus or airway 
inflammation.
When the pressure drop over the airways stays the same (force exerted to inhale stays equal) but 
the airways become smaller (because of eg, obstructions or inflammation), the flow rate will become smaller (there will be less liters of air flowing through these smaller airways in 1 second than when airways are bigger), leading to a higher resistance. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 54If the lung wants to compensate the higher resistance encountered in the lung, it will need to exert 
a higher pressure drop. Specific image-based resi stance (siRaw) is similar to the image-based 
resistance (iRaw), but it takes the changes of the lung volume into account.
A study to evaluate the use of functional imaging to visualize and quantify airway involvement in 
asthma and COPD evaluated the correlation between FEV 1and FRI-based airway volumes. 
Evaluated the correlation between FEV 1and FRI-based airway resistance, in which a 10% change 
in FEV 1corresponded to a change of 25% in airway resistance ( Figure 3 )(Lanclus et al. 
Respi[INVESTIGATOR_125386]).
Figure [ADDRESS_141029] resistance
Mucus score
University of [LOCATION_004], San Francisco (UCSF researchers (John Fahy’s research group) have 
developed a new method to measure the burden of intraluminal mucus using Multi-detector Computed Tomography (MDCT) by [CONTACT_125474]. This technology has been validated in participants withasthma using CT scans with normal dose radiation protocols ( 39).
A high mucus score (plugs in ≥4 segments) occurred in 67% of subjects with asthma with FEV
1
of less than 60% of predicted volume, 19% with FEV 1of 60% to 80%, and 6% with FEV 1greater 
than 80% ( P< 0.001). N=146, among those 96 were severe asthma participants (65%) ( 39).
Functional Respi[INVESTIGATOR_125387]-opening of airways due to  intrapulmonary percussive ventilation in COPD 
participants ( 40).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141030] wall volume/airway lumen ratio para meter can be derived from the FRI parameters 
airway wall volume and airway volume. Airway wa ll thickness can be derived from this as well 
(and can be shown in discreet locations).
After a treatment with ICS in asthma an increase  in airway lumen volume (iVaw) and a reduction
in airway wall volume (iVaww) can be observed. The ef fect size of iVaw is larger than effect size 
iVaww due to the better resolution of iVaw in HRCT. Similar findings were observed by [CONTACT_125475] ( 41).
Lobar volumes
By [CONTACT_125476][INVESTIGATOR_125388], the lung volume (L) can 
be determined from the scans at both FRC and TLC. During segmentation, identifying the fissure planes on the CT images and using these surfaces  as cutting objects can separate lung lobes. 
Therefore, not only the total lung volume is determined, but also the volume of each lobe individually, which allows to pi[INVESTIGATOR_125389] l regional physiological changes of the airways 
and the lobe volumes.
The HRCT scans assessment will be performed by [CONTACT_18014]. Further details on the 
procedure will be provided in a separate instruc tions manual. The wash out period of asthma 
controllers and rescue medication be fore HRCT scan is detailed in the Table 4 (Section 8.1 ).
If HRCT scan cannot be performed at D1 due to lo gistic reasons, it can be scheduled the next day. 
In this particular situation the investigator should ensure that the IMP loading dose is administered 
after the HRCT scan, at D1+[ADDRESS_141031]-BD FEV1 or after 
spi[INVESTIGATOR_038] (in the latter case the wash-out period of SABA should be ensured), as per Investigator's decision.
8.2 SAFETY ASSESSMENTS 
Planned time points for all safety assessments are provided in the SoA ( Section 1.3 ).
8.2.1 Physical examinations
xA complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal and neurological systems. Height and weight 
will also be measured and recorded. Height (cm) will be measured only at the screening visit (V1).
xInvestigators should pay special attention to clinical signs related to previous serious 
illnesses.
xAny new finding or worsening of previous finding should be reported as a new AE.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 568.2.2 Vital signs
xTemperature (degrees Celsius), heart rate (beats per minute), respi[INVESTIGATOR_697] (breaths per 
minute), and blood pressure (mmHg) will be assessed.
xBlood pressure and pulse measurements will be assessed in semi-supi[INVESTIGATOR_125390] a co mpletely automated device. Manual techniques 
will be used only if an automated device is  not available. Blood pressure and pulse will be 
measured prior to receiving investigational product at the clinic visits.
xBlood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_141032] 
for the participant in a quiet setting without distractions (eg, television, cell phones).
xRefer to Section 1.3 for the schedule of vital signs performed throughout this study.
8.2.3 Electrocardiograms
xSingle 12-lead electrocardiogram (ECG ) will be obtained as outlined in the SoA (see 
Section 1.3 ) using an ECG machine that automatically calculates the heart rate and 
measures PR, QRS, QT, and QTc intervals.
8.2.4 Clinical safety laboratory assessments
xSee Appendix 2 ( Section 10.2 ) for the list of clinical laboratory tests to be performed and 
to the SoA ( Section 1.3 ) for the timing and frequency.
xThe Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes meeting the AE definition ( Section 10.3 ) occurring during the 
study in the AE section of the e-CRF. The laboratory reports must be filed with the source 
documents. Clinically significant abnormal laboratory findings are those which are not 
associated with the underlying disease, unless judged by [CONTACT_125477]'s condition.
xAll laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline 
or are no longer considered clinically significant by [CONTACT_113543].
- If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737], the etiology should be identified and the Sponsornotified.
- All protocol-required laboratory assessments, as defined in Appendix 2 ( Section 10.2 ),
must be conducted in accordance with the SoA ( Section 1.3 ).
- If laboratory values from non-protocol-specified laboratory assessments performed at 
the institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_737] (eg, SAE or AE or dose modification), then the results must be recorded in the e-CRF.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141033] (AESI) is an AE (serious or nonserious) of scientific and 
medical concern specific to the Sponsor ’s product or program, for which ongoing monitoring and 
immediate notification by [CONTACT_125478]. Such events may require further investigation in order to characterize and understand them. Adverse events of special 
interest may be added, modified or removed during a study by [CONTACT_12548].
For these AESIs, the Sponsor will be informed immediately (ie, within 24 hours), per SAE 
notification described in Section 8.3.4 , even if not fulfilling a seriousness criterion, using the
screens in the e-CRF.
xClinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms).
xAnaphylactic reactions.
xSystemic hypersensitivity reactions.
xHelminthic infections.
xKeratitis
xAny severe type of conjunctivitis or blepharitis
xSignificant ALT elevation:
- ALT >[ADDRESS_141034] in participants with baseline ALT ≤[ADDRESS_141035]; 
or
- ALT >[ADDRESS_141036] if baseline ALT >[ADDRESS_141037].
“Baseline” refers to ALT sampled at baseline visit or, if baseline value is unavailable, 
to the latest ALT value before the baseline visit
xPregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP;
- Pregnancy occurring in a female participant entered in the clinical trial or in a female 
partner of a male participant entered in the clinical trial. It will be qualified as an SAE only if it fulfills one of the seriousness criteria,
- In the event of pregnancy in a female participant, IMP should be discontinued,- Follow-up of the pregnancy in a female par ticipant or in a female partner of a male 
participant is mandatory until the outcome has been determined.
- Any pregnancy complication or elective termination of a pregnancy for medical 
reasons will be reported as an AE or SAE.
- Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pr egnancy) are considered SAEs.
xSymptomatic overdose (serious or nonserious) with IMP/NIMP.
xAn overdose (accidental or intentional) with the IMP is an event suspected by [CONTACT_125479] 11 days. The circumstances (ie, accidental or 
intentional) should be clearly specified in the verbatim and symptoms, if any, entered on separate adverse event forms.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 58An overdose (accidental or intentional) with any NIMP is an event suspected by [CONTACT_125480]. The 
circumstances (ie, accidental or intentional) should be clearly specified in the overdose form.
The definitions of an AE or SAE can be found in Appendix 3 ( Section 10.3 ).
Adverse event will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant's legally authorized representative). 
The Investigator and any qualified designees ar e responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study intervention or study procedures, or thatcaused the participant to discontinue the IMP (see Section 7 ).
8.3.1 Time period and frequency for collecting AE and SAE information
All SAEs will be collected from the signing of the ICF until the follow-up visit at the time points 
specified in the SoA ( Section 1.3 ).
All AE will be collected from the signing of the ICF at the time points specified in the SoA 
(Section 1.3 ).
All SAEs and AESI will be recorded and report ed to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 3 ( Section 10.3 ).
The Investigator will submit any updated SAE data to the Sponsor within 24 hours of it being available.
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the Investigator must promptly notify the Sponsor.
8.3.2 Method of detecting AEs and SAEs
The method of recording, evaluating, and assessing  causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section 10.3 ).
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.
8.3.3 Follow-up of AEs and SAEs
After the initial AE/AESI/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. At the pre-specified study end-date, all SAEs, and
nonserious AESIs (as defined in Section 8.3 ) will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
Further information on follow-up procedures is given in Appendix 3 ( Section 10.3 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 598.3.4 Regulatory reporting requirements for SAEs
xPrompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.
xThe Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with  country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.
xSerious adverse events that are considered ex pected will be specified in the reference 
safety information (IB).
xInvestigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regulatory requirements and Sponsor policy and forwarded to Investigators as necessary.
xAn Investigator who receives an Investigator safety report describing an SAE, S[LOCATION_003]R or 
any other specific safety information (eg, summary or listing of SAEs) from the Sponsor will re view and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements. It is the responsibility of the Sponsor to assess whether an event meets the criteria for a S[LOCATION_003]R, and therefore, is expedited to regulatory authorities.
8.3.5 Pregnancy
xDetails of all pregnancies in female participants  and female partners of male participants
will be collected after the start of study intervention and until the outcome has been 
determined .
xIf a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of
learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section 10.4 ).
xAbnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.
xThe participant /pregnant female partner will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow-up information on the participant /pregnant female partner and the neonate and the info rmation will be forwarded to the Sponsor.
xAny post-study pregnancy-related SAE considered reasonably related to the study 
intervention by [CONTACT_78795]. While the Investigator is 
not obligated to actively seek this informa tion in former study participants /pregnant 
female partner, he or she may learn of an SAE through spontaneous reporting.
xAny female participant who becomes pregnant while participating in the study will 
discontinue the study intervention.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141038] complaint form within required timelines.
Appropriate information (eg, samples, labels or do cuments like pi[INVESTIGATOR_12989]) related to 
product identification and to the potential deficienci es may need to be gathered. The Investigator
will assess whether or not the quality issue has to be reported together with an AE or SAE.
8.[ADDRESS_141039] twice the intended dose during an 
interval of less than 11 days.
Symptomatic overdose (serious or nonserious) is an AESI (defined in Section 8.3 ). No antidote is 
available for dupi[INVESTIGATOR_12458].
In the event of an overdose, the Investigator should:
1. Contact [CONTACT_27465].2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
dupi[INVESTIGATOR_125391].
3. Obtain a plasma sample for pharmacokinetic analysis as soon as possible from the date of 
the last dose of study intervention if request ed by [CONTACT_1689] (determined on a 
case-by-case basis).
4. Document appropriately in the e-CRF.
Decisions regarding dose interruptions or modifications will be made by [CONTACT_125481].
8.5 PHARMACOKINETICS
Pharmacokinetic parameters are not evaluated in this study.
8.6 PHARMACODYNAMICS
Pharmacodynamic variables/biomarkers:
xFractional exhaled nitric oxide (FeNO) levels.
Fractional exhaled nitric oxide s hould be conducted prior to spi[INVESTIGATOR_125392] a fast of
≥1 hour. Further details on the procedure for measuring FeNO will be provided in a separate 
instruction manual. Fractional exhaled nitric oxide levels will be measured at the time points mentioned in the SoA ( Section 1.3 ).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 618.7 GENETICS
Pharmacogenetic/pharmacogenomic tes ting is not performed in this study.
8.8 BIOMARKERS
xWhole blood biomarkers: blood eosinophil count.
Eosinophil counts will be measured at the time points requested mentioned in the SoA 
(Section 1.3 ).
8.[ADDRESS_141040] participant response to treatment. Therefore, data will be stored and used for future research when consented to by [CONTACT_4317] (see Section 10.1.3 ) unless prohibited by [CONTACT_125482]/IECs.
For participants who consent to the storage and use of their data, data may be used after the study 
ends for future research related either to the drug, the mechanism of action, and the disease or its 
associated conditions.
In the event future research is conducted for other purposes, the study participants will be 
informed of those purposes and will be given means to object to those research projects.
Data will be used in compliance with the information provided to participants in the ICF Part 2 
(future research).
All study participant data will be coded such that no participant direct identifiers will be linked to 
them. Coded data may be transferred to a Spons or site (or a subcontractor site), which may be 
located outside of the country where the study is conducted. The Sponsor adopts safeguards for 
protecting participant confidentiality and personal data (see Section 10.1.4 ).
Study participant coded data will be stored for future research for up to 25 years after the end of 
the study. If data are still considered of import ant scientific value afte r this period, coded data 
already available will be anonymized un less otherwise required by [CONTACT_5751].
Participant’s coded data sets provided to researchers for a specific research project will be 
available to the researchers for a maximum of [ADDRESS_141041] (end of 
project is defined by [CONTACT_125483]).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 629 STATISTICAL CONSIDER ATIONS
9.1 STATISTICAL HYPOTHES ES
For comparison of dupi[INVESTIGATOR_125393], the following hypotheses of the 
2primary endpoints will be tested.
1.Null hypothesis: 1)the proportion of participants achieving response of Fe No<25 ppb at 
Week 24 is the same between dupi[INVESTIGATOR_24767] p lacebo group; 2) the percentage change 
from baseline in untrimmed distal [s]iVaw is the same between dupi[INVESTIGATOR_125394] .
2.Alternative hypothesis: 1) the proportion of participants achieving response of 
FeNo<25ppb at Week 24 is different between d upi[INVESTIGATOR_125395]; 2) the 
percentage change from baseline in untr immed distal [s]iVaw is different between 
dupi[INVESTIGATOR_125395].
9.2 SAMPLE SIZE DETERMIN ATION AND PRESERVATION OF TYPE I ERROR FOR TH E
PRIMARY ENDPOINTS
To control the type -I error rate for the 2primary endpoints, a hierarchical testing procedure will 
be applied at a 2 -sided 5% significance level, ie ,each hypothesis will be formally tested only if 
the preceding one is significant at 5% level. The hierarchy of the tests for primary endpoints will 
be:
1.Proportion of participants achieving response of FeNO <25 ppb at Week 24
2.Percentage change from baseline to Week  24 in untrimmed distal [s]iVaw at TLC
Assumptions for the [s]iVaw parameter were based on extrapolating the limited available data in 
asthma looking at associations between FEV 1and lung imaging param eters .Clinically meaningful 
differ ences for the imaging parameters have not yet been established. However, expert opi[INVESTIGATOR_125396], such as 
pre-BD FEV 1mentioned above. 
By [CONTACT_125484] 1change from baseline at Week 24 with proportion of p articipants achieving 
response of FeNO <25ppb at Week 24 as one of the primary endpoints ,
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 63With the original assumptions for [s]iVaw, 87evaluable participants will provide approximately 
64% power with two -sample t -test at 2 -sided 0.05 significance level.
9.3 POPULATIONS FOR ANAL YSES
For purposes of analysis, the following populations are defined ( Table 6):
Table 6-Populations for analyses
Population Description
Screened All participants who sign the informed consent form 
Randomized Randomized participants consist of all participants with a treatment kit number allocated and recorded in 
the IVRS database, regardless of whether the treatment kit was used or not.  
Participants treated without being randomized will not  be considered as randomized and will not be 
included in any efficacy population.  Data from these participants  will be summarized separately.  
Intent-to-treat (ITT) The analysis population for the efficacy endpoints will be the intent-to-treat population: all randomized 
participants will be included in the ITT population, and analyzed acco rding to the treatment group 
allocated by [CONTACT_17628].  
Safety The safety population will include all randomized part icipants who received at least 1 injection of IMP.  
For safety analyses, participants will be analyzed  according to the trea tment actually received. 
9.4 STATISTICAL ANALYSES
The statistical analysis plan will be developed and finalized before database lock and will describe 
the participant populations to be included in th e analyses, and procedures for accounting for 
missing, unused, and spurious data. This s ection is a summary of the planned statisti cal analyses 
of the primary and secondary endpoints.
9.4.1 Efficacy analyses
All efficacy analyses will be performed on the Intent -to-treat ( ITT)population, unless otherwise 
noted.
Note that at each scan, images will be taken from each zone of the lung, thus there will be 
multiple observations per visit for each imaging parameter .Data may be logarithmically 
transformed prior to analysis if extreme skewness was observed based on blin ded data review.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 64Table 7 - Efficacy analyses
Endpoint Statistical Analysis Methods
Primary
x Proportion of participants achieving  FeNO 
<25 ppb at Week 24   
x  The primary analysis will be conducted by [CONTACT_125427]-Mantel-
Haenszel (CMH) test adjusted by [CONTACT_81473]. 
Comparison of the proportion s of responders between 
dupi[INVESTIGATOR_125397], and corresponding 
odds ratios and 95% CI along with the p-value will be reported. For participants who discontinued the study 
treatment not due to COVD-19 pandemic, off-
treatment data 
will be used to determine the responder/non-responder status. For any participants disc ontinue the study treatment 
due to COVID-[ADDRESS_141042] volumes 
corrected for lung volume ((s)iVaw) at total 
lung capacity (TLC) x  Percent change from baseline to Week 24 in distal [s]iVaw at 
TLC will be analyzed using a mixed model repeated 
measures model (MMRM). The model will include percent 
change fr om baseline values up to We ek 24 as the response 
variable, and factors for treatm ent group, region (Eastern 
Europe/ROW), ICS dose level (medium/high), visit, treatment-by-visit interact ion, baseline value, and baseline-
by-visit interaction. An unstructured 
covariance matrix will be 
used to model the within participant errors. No imputations 
for missing values will be carried out. The least square (LS) 
mean of each treatment group, the LS mean difference 
between the dupi[INVESTIGATOR_125398] p and placebo, and the 
corresponding 95% CI of the differences and p- values will be 
provided. For participants who discontinued the study 
treatment not due to COVID-19 pandemic, off-treatment 
imaging data, as available, will be included in the analysis. 
For any participants who discontinued study treatment due 
to COVID-19, off-treatment data will be set to missing. Note: 
baseline value corresponds to  the baseline value of the 
variable being analyzed. In case of variables in the 
percentage scale, this will be the baseline value on the raw 
scale. 
Secondary
x Percent change from baseline to Week [ADDRESS_141043] volumes 
corrected for lung volume ((s)iVaw) at 
functional residual capacity (FRC) x Same as the primary imaging parameter. 
x Percent change from baseline to Week [ADDRESS_141044] resistance 
corrected for lung volume ((s)iRaw) at TLC x Same as above 
x Percent change from baseline to Week [ADDRESS_141045] resistance 
corrected for lung volume ((s)iRaw) at FRC x Same as above 
x Change from baseline to Week 24 in global lung lobar volumes (iVlobes) at TLC x Same as above.  
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141046]-based internal airflow distribution 
(IAD) for each lung zone x Same as above. 
x Change from baseline to Week 24 in 
image- based ventilation/perfusion (iV/Q) at 
TLC for each lung zone x Same as above.  
x Change from baseline to Week [ADDRESS_141047]-bronchodilator FEV 1 x Same as above. 
x Change from baseline to Week 24 in ACQ-
7 x Same as above. 
x Change from baseline to  Week 24 in global 
lung mucus scoring (UCSF mucus scoring) x Same as above. 
Exploratory x Will be described in the statistical analysis plan finalized 
before database lock. These will include investigating the 
relationship between key lung fu nction parameters, imaging 
parameters and biomarker levels. 
9.4.[ADDRESS_141048] dose + 12 weeks (or the day before switch to commercialized dupi[INVESTIGATOR_125399], whichever occurs first).
Table 8 - Safety analyses
Endpoint Statistical Analysis Methods
Secondary
x Incidence of TEAEs, TESAEs, 
TEAE leading to study intervention discontinuation and 
AESI  
x Adverse event incidence tables will be presented by [CONTACT_70244] (SOC) (sorted by [CONTACT_56496]), high- level group 
term (HLGT), high level term (HLT ) and preferred term (PT), the 
number (n) and percentage (%) of  participants experiencing an AE. 
Multiple occurrences of the same event in the same participant will be 
counted only once in the tables. Th e denominator for computation of 
percentages is the safety populat ion within each treatment group. 
x Proportion of participants with at least one TEAE, serious TEAE, 
AESI, and TEAE leading to discontinu ation of the study intervention 
will be tabulated by [CONTACT_63300]. In addition, TEAEs will be 
described according to maximum intensity and relation to the study 
drug. Serious AEs and AEs leading to study discontinuation that occur 
outside the treatment- emergent period will be  summarized separately. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141049] deviatio n, and LS means will also be provided.
9.4.3 Other analyses
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 9 ( Section 10.9 ). The sensitivity analysis may be conducted, and details 
will be specified in the Statistical Analysis Plan.
9.5 INTERIM ANALYSES 
Not applicable.
9.5.1 Data Monitoring Committee (DMC)
A DMC is not planned for this study.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 6710 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT
CONSIDERATIONS
10.1.1 Regulatory and ethical considerations
xThis study will be conducted in accordance with the protocol and with the following:
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and the applicab le amendments and Counc il for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines,
- Applicable ICH GCP Guidelines,
- Applicable laws and regulations (eg, data protection law as General Data Protection 
Regulation [GDPR]).
xThe protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_125485]/IEC before the study is initiated.
xAny amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
xProtocols and any substantial amendments to th e protocol will require health authority 
approval prior to initiation except for change s necessary to eliminate an immediate hazard 
to study participants.
xThe Investigator will be responsible for the following:
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC,
- Determining whether an incidental finding (as per [COMPANY_011] policy) should be returned to 
a participant and, if it meets the appropriate cr iteria, to ensure the finding is returned 
(an incidental finding is a previously undiagnosed medical condition that is discovered unintentionally and is unrelated to the aims of the study for which the tests are being 
performed). The following should be consider ed when determining the return of an 
incidental finding:
- The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so designated by [CONTACT_2299]) is consistent with all 
applicable national, state, or regional law s and regulations in the country where the 
study is being conducted, and
- The finding reveals a substantial risk of a serious health condition or has reproductive 
importance, AND has analytical validity, AND has clinical validity. 
- The participant in a clinical study has the right to opt out of being notified by [CONTACT_21481]. In the event that the participant has opted out of being notified and the finding has consequences for other individuals, eg, the 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141050] in the site 
medical files that she/he does not want to know about such findings
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures,
- Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.
As applicable, according to Directive 2001/20/EC, the Sponsor will be responsible for obtaining 
approval from the Competent Authorities of the EU  Member States and/or Ethics Committees, as 
appropriate, for any amendments to the clin ical trial that are deemed as “substantial” (ie, changes 
which are likely to have a significant impact on the safety or physical or mental integrity of the clinical trial participants or on the scientific value of the trial) prior to their implementation.
10.1.2 Financial disclosure
Investigators and sub-investigators will provid e the Sponsor with sufficient, accurate financial 
information as requested to allow the Spons or to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.
10.1.3 Informed consent process
xThe Investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized repre sentative and answer all questions regarding 
the study including what happens to the participant when his/her participation ends (posttrial access strategy for the study).
xParticipants must be informed that their par ticipation is voluntary. Participants or their 
legally authorized representative will be required to sign a statement of informed consent that meets the requirements of [ADDRESS_141051] (HIPAA) requirements, where applicable, and the IRB/IEC or study center.
xThe medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
xIn case of ICF amendment while the participants are still included in the study, they must 
be re-consented to the most current version of the ICF(s). Where participants are not in the 
study anymore, teams in charge of the amendment must define if those participants must or not re-consent or be informed of the amendment (eg, if th e processing of personal data 
is modified, if the Sponsor changes, etc).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 69xA copy of the ICF(s) must be provided to the participant or the participant’s leg ally 
authorized representative.
xParticipants who are rescreened are required to sign a new ICF.
xThe ICF contains 2 separate sections that addresses the use for research of participants’ 
data. Optional exploratory research must be detailed in the section “Optional tests/procedures” and future research is to  be defined in Core Study Informed Consent 
Form (CSICF) Part 2. Each option is subjec t to an independent consent and must be 
confirmed by [CONTACT_13158] a checkbox in CSICF Part  3. The Investigator or authorized designee 
will explain to each participant the objective s of the exploratory research and why data are 
important for future research. Participants will be told that they are free to refuse to 
participate and may withdraw their consen t at any time and for any reason during the 
storage period.
xFor a regional or national emergency declared by a governmental agency, contingency 
measures are included in Appendix 9 ( Section 10.9 ).
10.1.4 Data protection
All personal data collected and/or processed in relation to this study will be handled in 
compliance with all applicable Privacy & Data Protection laws and regulations, including the GDPR (General Data Protection Regulation). The study Sponsor is the [COMPANY_011] company responsible for ensuring compliance with this matter, when processing data from any individual 
who may be included in the [COMPANY_011] databases, including Investigators, nurses, experts, service providers, Ethics Committee members, etc. 
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor takes all appropriate me asures to safeguard and prevent access to this 
data by [CONTACT_13159].
Protection of participant dataData collected must be adequate, relevant and not excessive, in relation to the purposes for which 
they are collected. Each category of data must be properly justified and in line with the study objective.
Participant race and ethnicity will be collected in this study be /because they are required by 
[CONTACT_17513] (eg, on African American population for the FDA or on Japanese population for the Pharmaceuticals and Medical Devices Agency in Japan). They will not be collected in the 
countries where this is prohibited by [CONTACT_1295].
xParticipants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor or its service providers, when applicable, will 
be identifiable only by [CONTACT_13160]; participant names or any information which would make the participant identifiable will not be transferred to the Sponsor.
xThe participant must be informed that his/her personal study-related data will be used by 
[CONTACT_13161]. The level of disclosure 
must also be explained to the participant as described in the informed consent.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141052] be informed that his/her medical records may be examined by 
[CONTACT_9325], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].
xParticipants must be informed that their study-related data will be used for the whole “drug 
development program”, ie, for this trial as well as for the following steps necessary for the development of the investigational product, incl uding to support negotiations with payers 
and publication of results.
Protection of data related to professionals involved in the study 
xPersonal data (eg, contact [CONTACT_8972], affiliati on(s) details, job title and related professional 
information, role in the study, professional resume, training records) are necessary to allow [COMPANY_011] to manage involvement in the study and/or the related contractual or 
pre-contractual relationship. They may be communicated to any company of the [COMPANY_011] 
group (“[COMPANY_011]”) or to [COMPANY_011] service providers, where needed.
xPersonal data can be processed for other studies and projects. At any time, objection to 
processing can be made by [CONTACT_13164] (link available at [COMPANY_011].com). 
xIn case of refusal to the processing of personal data by [CONTACT_13165], it will be 
impossible to involve the professionals in any Sa nofi study. In case the professionals have 
already been involved in a [COMPANY_011] study, they will not be able to object to the processing of their personal data as long as they are required to be processed by [CONTACT_5279]. The same rule applies in case the professionals are listed on a regulatory agencies disqualification list.
xPersonal data can be communicated to the following recipi[INVESTIGATOR_840]: 
- Personnel within [COMPANY_011] or partners or service providers involved in the study 
- Judicial, administrative and regulatory aut horities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the framework of judicial or administrative proc edures. Contact [CONTACT_125486] e Economic European 
Area, in countries where the legislation doe s not necessarily offer the same level of data 
protection or in countries not recognized by [CONTACT_125487]. Those transfers are safeguarded by [CONTACT_125488], notably: 
- The standard contractual clauses of the European Commission for transfers towards 
our partners and service providers,
-[COMPANY_011]’s Binding Corporate Rules for intra -group transfers. 
xProfessionals have the possibility to lodge a complaint with [COMPANY_011] leading Supervisory 
Authority, the “Commission Nationale de l’Informatique et des Libertés” (CNIL) or with any competent local regulatory authority.
xPersonal data of professionals will be retained by [CONTACT_13169] (30) years, unless 
further retention is required by [CONTACT_5279].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 71xIn order to facilitate the maintenance of Inve stigators personal data, especially if they 
contribute to studies sponsored by [CONTACT_13170], [COMPANY_011] participates in the Shared Investigator Platform (SIP) and in the TransCelerate Investigator Registry (IR) project (https://transceleratebiopharmai nc.com/initiatives/investigator-registry/). 
Therefore, personal data will be securely shared by [CONTACT_125489]. This sharing allows Investigators to keep their data up-to-date once for all across pharm aceutical companies participating in the 
project, with the right to object to the transfer of the data to the TransCelerate project. 
xProfessionals have the right to request the ac cess to and the rectification of their personal 
data, as well as their erasure (where applicable) by [CONTACT_13164]: [COMPANY_011] DPO - 54 rue La Boétie - [ZIP_CODE] PARIS - [LOCATION_009] (to contact [CONTACT_13173], visit https://www.sa nofi.com/en/our-responsibility/sanofi-global-privacy-
policy/contact).
10.1.5 Committees structure
Study committees: Not applicable
10.1.6 Dissemination of clinical study data and results
Study participants
At the end of the clinical study, the Sponsor may publish the study results in scientific journal(s). 
As part of the review for publication, indepe ndent scientists may need to use “coded” data of all 
the study participants to independently verify the study’s results.
[COMPANY_011] shares information about clinical trials an d results on publicly accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other clinical trial disclosure commitments establishe d by [CONTACT_13174]. These 
websites include ClinicalTrials.gov, EU clinicaltri alregister (eu.ctr), and sanofi.com, as well as 
some national registries. For pediatric and a dult trials, the results will generally be 
submitted/released 6 and 12 months, respectively, after the end of the clinical trial worldwide 
(ie, the last active, participating country).
In addition, results from clinical trials in participants are required to be submitted to 
peer-reviewed journals following internal comp any review for accuracy, fair balance and 
intellectual property. For those journals that request  sharing of the analyzable data sets that are 
reported in the publication, interested researchers ar e directed to submit their request to vivli.org.
Individual participant data and supporting clinical documents are available for request at vivli.org.
While making information available we continue to protect the privacy of participants in our 
clinical trials. Details on data sharing criteria and process for requesting access can be found at this web address: vivli.org.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 72Professionals involved in the study or  in the drug development program
[COMPANY_011] may publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, made to healthcare organizations and 
professionals and/or any direct or indirect advant ages and/or any related information or document 
if required by [CONTACT_1289], by [CONTACT_13175] a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of Value from Pharmaceut ical Companies to Healthcare Professionals and 
Healthcare Organisations”.
10.1.7 Data quality assurance
xAll participant data relating to the study will  be recorded on e-CRF unless transmitted to 
the Sponsor or designee electronically (eg, laboratory data). The Investigator is
responsible for verifying that data entries are accurate and correct by [CONTACT_125490] e-CRF.
xGuidance on completion of CRFs will be prov ided in the CRF Completion Instructions.
xThe Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
xMonitoring details describing strategy (eg, ri sk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring technique s (central, remote, or on-site monitoring) 
are provided in separate study documents.
xThe Sponsor or designee is responsible for the data management of this study including
quality checking of the data.
xThe Sponsor assumes accountability for actions delegated to other individuals 
(eg, Contract Research Organizations).
xStudy monitors will perform ongoing source data verification to confirm that data entered 
into the e-CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and thatthe study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.
xRecords and documents, including signed ICFs, pertaining to the conduct of this study
must be retained by [CONTACT_13177] 25 years after the signature [CONTACT_125504] a longer retention period. No records may be destroyed during the retenti on period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.
10.1.8 Source documents
xSource documents provide evidence for the exis tence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator ’s site.
xData entered in the e-CRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The Investigator may 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141053] be available.
xDefinition of what constitutes source data: Source data is all information in original 
records and certified copi[INVESTIGATOR_125400], observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.Source data are contained in source documen ts. Source documents are original documents, 
data and records such as hospi[INVESTIGATOR_1097], clinic and office charts, laboratory reports, notes, memoranda, pharmacy dispensing records, recorded data from automated instruments etc. Data downloaded from the laboratories, spi[INVESTIGATOR_038], FeNO measurement, ECG, forced oscillometry, HRCT scans, home dosing diary and asthma background therapy diary, paper questionnaires (ACQ- 7, AQLQ[S]) will be considered source data.
xThe Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
xStudy monitors will perform ongoing source da ta verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.
10.1.[ADDRESS_141054] particip ant screened and will be the study start date.
Study/Site termination
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of th e Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have been collected and a study site closure visit has been performed.
The Investigator may initiate study site closure at  any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for study termination by [CONTACT_1034], as we ll as reasons for the early closure of a study 
site by [CONTACT_125491]:
xFor study termination:
- Information on the product leads to doubt as to the benefit/risk ratio,
- Discontinuation of further study intervention development.
xFor site termination:
- Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines ,
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 74- Inadequate or no recruitment (evaluate d after a reasonable amount of time) of 
participants by [CONTACT_737],
- Total number of participants included earlier than expected.
If the study is prematurely terminated or suspended, the Sponsor should promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The investigators shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.
10.1.[ADDRESS_141055] editorial and ethical  practice, the Sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator w ill be designated by [CONTACT_11402].
xAuthorship will be determined by [CONTACT_14346].
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS
xThe tests detailed in Table 9 will be performed by [CONTACT_125469].
xProtocol-specific requirements for inclusion or  exclusion of participants are detailed in 
Section 5 of the protocol.
xAdditional tests may be performed at any ti me during the study as determined necessary 
by [CONTACT_9332].
xPregnancy testing as mentioned in the SoA ( Section 1.3 ).
Table 9 - Protocol-required laboratory assessments
Laboratory assessments Parameters
Hematology Eosinophil count 
Other screening tests Highly sensitive (Serum at screening and urine at the other visits) human chorionic 
gonadotropin (hCG) pregnancy test (as needed for women of childbearing potential). 
 Hepatitis screening covering hepatitis B surface  antigen (HBsAg), total hepatitis B core 
antibody (total HBcAb) including IgM HBcAb; he patitis C virus antibodies (HCVAb). In 
case of results showing HBs Ag (negative), and HBcAb (positive), an HBV DNA testing 
will be performed to rule out a false positivi ty if the Investigator believes the participant is a 
false positive, or to clarify the serological st atus if the Investigator finds it unclear to 
interpret in absence of known HBV infection. In case of result s showing HCVAb (positive), 
an HCV RNA testing may be performed to rule out a false positivity, if the Investigator 
believes the participant is a false positive. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 75Laboratory assessments Parameters
 Human Immunodeficiency Virus (HIV) scree ning (Anti-HIV-1 and HIV-2 antibodies). 
 Tuberculosis testing would only be performed on  a country by [CONTACT_125492] s if required by [CONTACT_125493]. 
 The results of each test must be entered into the e-CRF 
NOTES : 
Details of liver chemistry stoppi[INVESTIGATOR_125401]- up assessments after liver stoppi[INVESTIGATOR_125402]  7.1.1  and Appendix 5 ( Section  10.5). Although the liver function te sts are not requested in the protoc ol, the routinely done lab tests 
might identify increased values of ALT, bilirubin.  All events related to ALT, bilirubin whi ch may indicate severe live r injury (possible Hy’s Law) 
must be reported as an SAE.  
Investigators must document their review of each laboratory safety report. 
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING
DEFINITION OF AE
AE definition
xAn AE is any untoward medical occurrence in a participant or clinical study participant, 
temporally associated with the use of study inte rvention, whether or not considered related 
to the study intervention.
xNOTE: An AE can therefore be any unfavora ble and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention.
Definition of unsolicited and solicited AE
xAn unsolicited adverse event is an adverse event that was not solicited using a home 
dosing diary and that is communicated by a participant who has signed the informed 
consent. Unsolicited AEs include serious and non-serious AEs.
xPotential unsolicited AEs may be medically attended (ie, symptoms or illnesses requiring a 
hospi[INVESTIGATOR_11956], or emergency room visit, or vi sit to/by a health care provider). The 
participants will be instructed to contact [CONTACT_3433] e site as soon as possible to report medically 
attended event(s), as well as any events that, though not medically attended, are of participant concern. Detailed information about reported unsolicited AEs will be collected 
by [CONTACT_14348]’s records.
xUnsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_125494].
xSolicited AEs are predefined local and systemic events for which the participant is 
specifically questioned, and which are noted by [CONTACT_125495].
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141056] results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medicaland scientific judgment of the Investigator (ie, not related to progression of underlying 
disease), eg:
- Symptomatic and/or,- Requiring either corrective treatment or consultation, and/or,- Leading to IMP discontinuation or modification of dosing, and/or,- Fulfilling a seriousness criterion, and/or,- Defined as an AESI.
xExacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
xNew conditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.
xSigns, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
xSigns, symptoms, or the clinical sequelae of a suspected overdose of either study
intervention or a concomitant medication.
x"Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will  be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE or SAE.
xThe signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, "lack of efficacy" or "failure of expected pharmacological action" also constitutes an AE or SAE.
Events NOT meeting the AE definition
xAny clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_78782]’s condition.
xThe disease/disorder being studied or expec ted progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s condition.
xMedical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to
the procedure is the AE.
xSituations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
xAnticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 77DEFINITION OF SAE
If an event is not an AE per definition above, then  it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease).
A SAE is defined as any adverse event that, at any dose:
a) Results in death.b) Is life-threatening:
The term “ life-threatening ”in the definition of “serious ”refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.
c) Requires inpatient hospi[INVESTIGATOR_32957]:
In general, hospi[INVESTIGATOR_125403] e participant has been detained (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d) Results in persistent disability/incapacity
-The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
- This definition is not intended to incl ude experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
e) Is a congenital anomaly/birth defectf) Other situations:
- Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_125404]. These events should usually be 
considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in
an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_18543], or development of drug dependency 
or drug abuse.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 78RECORDING AND FOLLOW-UP OF AE AND/OR SAE
AE and SAE recording
xWhen an AE/SAE occurs, it is the responsibility of the Investigator to review all
documentation (eg, hospi[INVESTIGATOR_1088], labor atory reports, and diagnostics reports) 
related to the event.
xThe Investigator will then record all relevant AE/SAE information in the e-CRF.
xIt is notacceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor’s representative in lieu of completion of the AE/SAE e-CRF page.
xThere may be instances when copi[INVESTIGATOR_125405]’s representatives . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_12997]’s representatives .
xThe Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of intensityThe Investigator will make an assessment of inte nsity for each AE and SAE reported during the 
study and assign it to one of the following categories:
xMild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and 
not interfering with everyday activities.
xModerate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.
xSevere: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a SAE. Seve re is a category utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “ serious ”when it meets at least one of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of causality
xThe Investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.
xA "reasonable possibility" of a relationship conve ys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
xThe Investigator will use clinical judgment to determine the relationship.
xAlternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study interventionadministration will be considered and investigated.
xThe Investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 79xFor each AE/SAE, the Investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provi ded an assessment of causality.
xThere may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Sponsor’s representatives . However, it is 
very important that the Investigator always  make an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor’s 
representatives.
xThe Investigator may change his/her opi[INVESTIGATOR_9242]-up information 
and send a SAE follow-up report with the updated causality assessment.
xThe causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
xThe Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_1034]’s 
representatives to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
xIf a participant dies during participation in the study or during a recognized follow-up
period, the Investigator will provide the Sponsor’s representatives with a copy of any post-
mortem findings including histopathology.
xNew or updated information will be recorded in the originally completed e-CRF.
xThe Investigator will submit any updated SAE data to the Sponsor ’s representatives within 
24 hours of receipt of the information.
REPORTING OF SAEsSerious adverse ev ent reporting to the Sponsor’s representatives via an electronic data 
collection tool
xThe primary mechanism for reporting an SAE to the Sponsor’s representatives will be the 
electronic data collection tool.
xIf the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) in order to report the event within 24 hours.
xThe site will enter the SAE data into the electronic system as soon as it becomes available.
xAfter the study is completed at a given site, th e electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.
xIf a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electroni c data collection tool has been taken off-
line, then the site can report this information on a paper SAE form (see next section) or to theSponsor’s representatives by [CONTACT_756].
xContacts for SAE reporting can be found in the CTP.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 80Serious adverse ev ent reporting to the Sponsor’s representatives via paper CRF
xFacsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor ’s representatives .
xIn rare circumstances and in the absence of  facsimile equipment, notification by [CONTACT_13186] a copy of the SAE data co llection tool sent by [CONTACT_13187].
xInitial notification via telephone does not replace the need for the Investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.
xContacts for SAE reporting can be found in the CTP.
10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION
DEFINITIONS:
Woman of childbearing potential (WOCBP)A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below).
xA postmenopausal state is defined as the peri od of time after a woman has experienced no 
menses for 12 consecutive months without an alternative medical cause.
xA high follicle-stimulating hormone level in the postmenopausal range may be used to 
confirm a postmenopausal state in women not  using hormonal contraception or hormonal 
replacement therapy (HRT).
xFemales on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective cont raception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
Permanent sterilization methods include:
xDocumented hysterectomy
xDocumented bilateral salpi[INVESTIGATOR_125406], (eg, Mullerian agenesis, androgen inse nsitivity, gonadal dysgenesis), investigator 
discretion should be applied to de termining study entry eligibility.
Note: Documentation can come from the site pers onnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
If fertility is unclear (eg, amenorrhea in adol escents or athletes) and a menstrual cycle cannot be 
confirmed before first administration of stud y intervention, additional evaluation should be 
considered.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 81Women in the following cate gories are considered WONCBP:
1. Any female with permanent infertility due to one of the following:
- Documented hysterectomy,- Documented bilateral salpi[INVESTIGATOR_1656],- Documented bilateral oophorectomy.For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, Mullerian agenesis, androgen inse nsitivity, gonadal dysgenesis), Investigator 
discretion should be applied to determining study entry.
2. Postmenopausal female
A postmenopausal state is defined as the peri od of time after a woman has experienced no 
menses for 12 consecutive months without an alternative medical cause.
- A high follicle-stimulating hormone level in the postmenopausal range 
[may/should/must] be used to confirm a postmenopausal state in women not using hormonal contraception or HRT. 
- Females on HRT and whose menopausal status is in doubt must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
CONTRACEPTION GUIDANCEIf locally required, acceptable c ontraceptive methods are limited to those which inhibit ovulation 
as the primary mode of action.
CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
Highly effective methodsbthat have low user dependency Failure rate of <1% per year when used 
consistently and correctly.
x Implantable progestogen-only hor mone contraception associated with inhibition of ovulation 
x Intrauterine device (IUD) 
x Intrauterine hormone-releasing system (IUS) 
x Bilateral tubal occlusion 
x Azoospermic partner (vasectomized or due to a medical cause) 
x Azoospermia is a highly effective contra ceptive method provided that the partne r is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm ha s been confirmed. If not, an additional highly effective 
method of contraception should be used.  
Note: documentation of az oospermia for a male participant can come from the si te personnel’s review of the participant’s medica l 
records, medical examination, or medical history interview. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 82Highly effective methodsbthat are user dependent Failure rate of <1% per year when used 
consistently and correctly.
x Combined (estrogen- and progestogen- containing) hormonal contraception as sociated with inhibition of ovulation 
- oral 
- intravaginal 
- transdermal 
- injectable 
x Progestogen-only hormone contraception associated with inhibition of ovulation 
- oral 
- injectable 
x Sexual abstinence 
x Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. 
a Contraceptive use by [CONTACT_125496]. 
b Failure rate of <1% per year when  used consistently and correctly. Typi[INVESTIGATOR_21361]. 
Note: Periodic abstinence (calendar, sympt othermal, post-ovulation methods), withdraw al (coitus interruptus), spermicides only,  and 
lactational amenorrhea method (LAM) are not acceptable methods of contraception for th is study. Male condom  and female condom s hould 
not be used together (due to risk of failure from friction). 
PREGNANCY TESTING:
xWOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive serum pregnancy test.
xAdditional urine pregnancy testing should be performed at each visit during the 
intervention period. In case of positive urin ary test during the study, a serum pregnancy 
test should be performed as soon as possible to confirm the pregnancy. A urine pregnancy 
test will be performed at home at the end of study visit.
xPregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected 
xPregnancy testing, with a sensitivity of ≥5 mIU/mL will be performed 
COLLECTION OF PREGNANCY INFORMATION: Male participants with partners who become pregnant 
xThe Investigator will attempt to collect pregnancy i nformation on any male participant’s 
female partner who becomes pregnant while th e male participant is in this study. This 
applies only to male participants who receive study intervention.
xAfter obtaining the necessary signed informed  consent from the pregnant female partner 
directly, the Investigator will record pregna ncy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregna ncy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141057] pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on the participant and the neonate and the information will be forwarde d to the Sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 we eks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, re gardless of fetal status (presence or absence 
of anomalies) or indication for the procedure.
xAny pregnancy complication or elective termina tion of a pregnancy will be reported as an 
AE or SAE. A spontaneous abortion is always considered to be an SAE and will be 
reported as such. Any post-study pregnancy related SAE considered reasonably related to 
the study intervention by [CONTACT_9341] 8.3.4 of the protocol. While the Investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
xAny female participant who becomes pregnant while participating in the study will 
discontinue study intervention.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 8410.5 APPENDIX 5: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-
UP ASSESSMENTS 
Although the liver fu nction tests are not requested in the protocol, the routinely done la b tests might identify increased valu es of ALT, bilirubin.
*If unable to retest in 72 hours, use original lab results to decide on furt her reporting/monitoring/discontinuation.
Note:“Baseline” refers to ALT sampled at baseline visit; or if baseli ne value unavailable, to the late st ALT sampled before the base line visit. The 
algorithm does not apply to the instances of increase in ALT during screening.
See Section 8.3.1 for guidance on safety reporting.
Normalization is defined as ≤ULN or baseline value, if baseline value is >ULN.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 8510.6 APPENDIX 6: LIST OF PROHIBITED LIVE ATTENTUATED VACCINES
xBacillus Calmette-Guérin (BCG) antituberculosis vaccine.
xChickenpox (Varicella).
xIntranasal influenza (FluMist-Influenza); inactive influenza vaccine delivered by [CONTACT_125497].
xMeasles (Rubeola).
xMeasles-mumps-rubella (MMR) combination.
xMeasles-mumps-rubella-varicella (MMRV) combination.
xMumps.
xOral polio (Sabin).
xOral typhoid.
xRotavirus.
xRubella.
xSmallpox (Vaccinia).
xVaricella Zoster (shingles).
xYellow fever.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 90
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 91
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 92
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 93
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group -strictly confidential Page 94
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 9510.8 APPENDIX 8: COUNTRY SPECIFIC REQUIREMENTS
Guidance on Contraceptive Methods
Highly effective contraceptive method of birth control may be defined according to the local
medical practice and regulations.
For Denmark:Highly effective contraceptive methods of birth control for participants enrolled in Denmark 
include:
xIntra-uterine devices (IUD).
xHormonal contraceptives (contraceptive pi[INVESTIGATOR_3353],  implants, transdermal patches, hormonal 
vaginal devices or injections with prolonged release).
xSubjects using a double-barrier contraceptiv e method (condom used with a diaphragm for 
example). However, this is limited to except ional cases or conditions where the participant
cannot use other contraceptive methods (ie, hormonal contraceptives or IUD).
xSubject having a sterilized permanent partner may be allowed to participate in the study.
The allowed methods of contraception can be  also described in the participant ’s information 
(subject information leaflet).
The above methods of contraception must be used in this study by [CONTACT_125498] [ADDRESS_141058] injection of study 
medication, covering more than 5 times the terminal half-life of IMP.
Sterilized or infertile subjects (defined as  having undergone surgical sterilization ie, 
vasectomy/bilateral tubectomy, hysterectom y and bilateral ovariectomy or as being 
postmenopausal defined as at least 12 months of amenorrhea prior enrolment) will be exempted 
from the requirements to use contraception in this study.
For [LOCATION_006]:
Adequate contraceptive measures include:
xPlacement of an IUD or intrauterine system (IUS).
xBarrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository. The use of barrier contraceptives should always be supplemented with the use of a spermicide.
xMale sterilization (with the appropriate post- vasectomy documentation of the absence of 
sperm in the ejaculate).
xTrue abstinence: When this is in line with the preferred and usual lifestyle of the subject.
[Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and 
withdrawal are not acceptable methods of contraception].
Age of Majority 
For Taiwan: The age of majority is in accorda nce to the most updated local regulation.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 9610.9 APPENDIX 9: CONTINGENCY MEASURES FOR A REGIONAL OR NATIONAL 
EMERGENCY THAT IS DECLARED BY A GOVERNMENTAL AGENCY
Continuation of the study in the event of a regional or national emergency declared by a
governmental agency:
For European countries contingency measures are currently only applicable for the COVID-19
pandemic.
A regional or national emergency declared by a governmental agency (eg, public health 
emergency, natural disaster, pandemic, terroris t attack) may prevent access to the clinical trial 
site.
Contingency procedures are suggested below a nd in sections (Section 2.3, Section 5.5, Section 
6.1, Section 7.1.2, Section [IP_ADDRESS], Section 8, Section 9.4.3, Section 10.1.3) for an emergency that 
prevents access to the study site, to ensure the safe ty of the participants, to consider continuity of 
the clinical study conduct, protect trial integrity, and assist in maintaining compliance with Good 
Clinical Practice in Conduct of Clinical Trials  Guidance. Sponsor agreement MUST be obtained 
prior to the implementation of these procedures for the duration of the emergency.
During the emergency, if the site will be unable to adequately follow protocol mandated 
procedures, screening may be temporarily delayed/halted (see also Section 5.5).
Attempts should be made to perform all assessments in accordance with the approved protocol to 
the extent possible. In case this is not possible due to a temporary disruption caused by [CONTACT_13193], focus should be given to assessments necessary to ensure the safety of participants 
and those important to preserving the ma in scientific value of the study.
Procedures to be considered in the event of a regional or national emergency declared by a 
governmental agency:
xIf onsite visits are not possible visit windows may be extended for the assessment of safety 
and/or efficacy data that cannot be obtained remotely (eg, spi[INVESTIGATOR_038], FeNO, FOT, HRCT
scan, vital signs).
xUse of local laboratory locations may be allowed.
xArrangements can be made for qualified si te personnel and/or health care professionals
(eg, visiting nurse service) for blood sample collection and study drug administration, if
allowed by [CONTACT_125451].
As an alternative to the on-site IMP dispensing, IMP may be supplied from the site to the
participant via a Sponsor-approved courier company where allowed by [CONTACT_125499].
Rechallenge: In case of missed dose(s), no loading dose of 2 injections will be administered when
restarting the treatment, whatever the number of missed doses. The participants should continue
their scheduled IMP treatment and visits, even if  more than 2 consecutive doses were missed.
Contingencies implemented due to emergency will be documented.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 97Statistical analysis: a sensitivity analysis may be conducted; details will be specified in the 
Statistical Analysis Plan.
For a regional or national emergency declared by a governmental agency, contingency proceduresmay be implemented for the duration of the emergency. The participants or their legally
authorized representative should be verbally informed prior to initiating any changes that are to beimplemented for the duration of the emergency (e g, study visit delays/treatment extension, use of
local labs).
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 9810.10 APPENDIX 10: RADIATION EXPOSURE
Radiation Expert Affidavit
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 99
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 100
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 101Health Physics Society-Radiation Exposure Risk-revision 2010.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 102
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 103
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page [ZIP_CODE].11 APPENDIX 11: ABBREVIATIONS
ACQ: Asthma Control Questionnaire 
AD: atopic dermatitisAE: adverse eventAESI: adverse event of special interestALT: alanine aminotransferaseAQLQ(S): Asthma Quality of Life Questionnaire with Standardized ActivitiesATS: American Thoracic SocietyCFR: Code of Federal Regulations
COPD: chronic obstructive pulmonary disease
COVID-19: coronavirus disease 2019CRSwNP: chronic rhinosinusitis with nasal polyposisCT: computed tomographyECG: electrocardiograme-CRF: electronic case report formEoE: eosinophilic esophagitisEOT: end of treatmentERS: European Respi[INVESTIGATOR_125407]: early treatment discontinuationFeNO: fractional exhaled nitric oxideFEV1: forced expi[INVESTIGATOR_3741] 1 second
FI: functional imaging
FOT: forced oscillation techniqueFRC: functional residual capacityFRI: functional respi[INVESTIGATOR_125408]: Good Clinical PracticeGDPR: General Data Protection RegulationHBcAb: hepatitis B core antibody HBsAg: hepatitis B surface antigen HCVAb: hepatitis C virus antibody HIV: human immunodeficiency virusHRCT: high-resolution computed tomographyHRT: hormonal replacement therapyIB: Investigator’s Brochure 
ICF: informed consent form
ICH: International Council for HarmonisationICS: inhaled corticosteroidsIEC: Independent Ethics CommitteesIMP: investigational medicinal productIRB: Institutional Review BoardsIUD: Intra-uterine deviceIVRS: interactive voice recognition systemIWRS: interactive web response system
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 105LABA: long- acting β2 agonists 
LTRA: leukotriene receptor antagonistMCID: minimal clinically important differenceMMRM: mixed model repeated measures model MoA: mechanism of action OCS: oral corticosteroidsPN: prurigo nodularisSABA: short- acting β2 agonists 
SAD: small airway dysfunctionSAE: serious adverse eventSoA: schedule of activities TB: tuberculosis
TEAE: treatment emergent adverse event
UCSF: University of [LOCATION_004], San Francisco ULN: upper limit of normal
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page [ZIP_CODE].12 APPENDIX 12: PROTOCOL AMENDMENT HISTORY
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the table of contents (TOC).
10.12.1 Amended protocol 02 (15 March 2021)
This amended protocol 02 is considered to be substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the Eu ropean Parliament and the Council of the 
European Union.
OVERALL RATIONALE FOR THE AMENDMENT
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
The main reasons for the amended protocol 02 are to introduce some clarifications in the 
eligibility criteria, to decrease the patient burden and to allow more flexibility for some of the study procedures (eg, FeNO assessment, complete  clinical examination, the sequence of the study 
procedures). We are also taking this opportunity to align the safety reporting (AESI) with the updated IB and to incorporate contingency measures in case of a regional or national emergency. 
The stratification factor related to regions has been  changed to Eastern Europe/ROW. In total, no
more than 40% participants shoul d be in "Eastern Europe" strata.
Section # and Name [CONTACT_23688]
1.1 Synopsis; 4.1 Overall design; 
6.3 Measures to minimize bias: 
randomization and blinding; 
9.4.1 Efficacy analyses The stratification factor related to regions has been changed to Eastern Europe/ROW. In total, 
no more than 40% participants should be in 
"Eastern Europe" strata. Differences in treatment effect of 
dupi[INVESTIGATOR_12458] [ADDRESS_141059] in EE vs ROW 
1.3 Schedule of Activities 
(SoA); 5.1 Inclusion criteria; 
8.1 Efficacy Assessments; FeNO will be rechecked at randomization. Ensure FeNO eligibility at V2 
 
Section 1.3 Schedule of Activities 
(SoA) Complete physical examinations will be 
performed at V1, V2, and V5. The number of complete physical 
examinations has been reassessed in order to decrease the participants’ 
burden. 
Retesting of FeNO one additional time during screening if the eligibility criterion for FeNO was 
not met at V1. FeNO will be re-checked at 
randomization visit (V2) for eligibility. To allow more flexibility for FeNO 
assessment during screening; to 
ensure that the FeNO eligibility criterion 
should be met at V2 as well. 
ACQ-[ADDRESS_141060] scan 
Added provision for retesting of spi[INVESTIGATOR_125409]-BD FEV1 at V1 Clarifications related to the retesting of 
pre-BD FEV1 during screening 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 107Section # and Name [CONTACT_125505] D1+[ADDRESS_141061] scan can’t be 
performed at V2 
Added note for contingency measures for a 
regional or national emergency and reference to 
the Appendix 9 Contingency measures in case of 
regional and national emergency 
Clarification added in footnote “r” regarding 
home dosing diary and asthma background 
therapy diary Clarification 
Section 2.3 Benefit/Risk 
Assessment Updated text related to dupi[INVESTIGATOR_125410]-marketing exposure 
Updated the ADRs list for dupi[INVESTIGATOR_125411]/risk assessment related to 
COVID-19 Regulatory and safety updates related 
to dupi[INVESTIGATOR_125412] 5.1 Inclusion Criteria I.06. Added provision for consideration of 
historical blood eosinophil count, and FeNO 
assessment at V2 as well. To clarify in the inclusion criterion I06 
that the historical values of blood 
eosinophil count measured within 
6 months prior to V1 in the absence of 
OCS treatment are allowed; FeNO to 
be assessed for eligibility at V2 as well 
I.09. Added provision for male contraception duration  Correction related to male contraception duration 
Section 5.2 Exclusion Criteria E.04. Added clarifications related to asthma exacerbation Clarifications on asthma exacerbation 
E09. Added exclusion provision for hepatic 
clinically significant disease, as judged by [CONTACT_125500] 
E14. Updated exclusion criterion for treatment 
with live (attenuated) vaccine Clarification of the criterion related to 
vaccination with live (attenuated) 
vaccine  
E15. Updated exclusion criterion regarding the 
treatment with oral corticosteroids (OCS) within 
2 weeks prior to V1 To clarify timeframe for OCS treatment 
E18. Updated exclusion criterion regarding the 
treatment with an investigational drug within 1 
month or within 5 half-lives (if known), 
whichever is longer, prior to V1. An interdiction of non-antibody 
investigational drugs for [ADDRESS_141062] during screening FeNo retesting allowed one additional 
time during scree ning: minor updates 
on spi[INVESTIGATOR_125413]-test 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 108Section # and Name [CONTACT_19523] 5.5  Criteria for 
Temporarily Delaying Screening, 
Randomization, or Study 
Intervention Administration Statement for provisions in  case of regional or 
national emergency added with reference to 
Appendix 9 (Section 10.9) Contingency measures in case of 
regional or national emergency 
Section 6.1 Study Intervention(s) 
Administered 
 Updates related to IMP ad ministration, patients’ 
instructions on hypersensitivity reactions and 
self-monitoring after the administration of IMP at 
home are added; Clarifications related to the IMP 
administration and monitoring after IMP 
administration 
Process in case of missed IMP doses is detailed 
 To clarify the process in case a 
participant misses IMP administration(s). The participants will 
not be prematurely discontinued from treatment in case they miss 
[ADDRESS_141063].  
Section 6.1 Study Intervention(s) 
Administered 
Section 6.5  Concomitant 
Therapy 
Section 6.6 Rescue Medicine Text added allowing systemic corticosteroids for 
the treatment of asthma exacerbations. Systemic corticosteroids are allowed 
for the treatment of asthma exacerbation 
Section 7.1.2  Temporary 
discontinuation 
 Updated criteria for  temporary discontinuation: 
xtreatment with a live (attenuated) vaccine 
xtreatment with immunomodulating biologics 
(including experiment al treatments) 
xsystemic corticotherapy (except the 
administration in case of asthma 
exacerbation) Clarification related to criteria for 
temporary discontinuation 
Section [IP_ADDRESS] Rechallenge 
Section 9.4.3  Other analyses Updates related to regional or national 
emergency are added Contingency measures in case of 
regional and national emergency 
Section 7.1.1 Definitive 
discontinuation Added definition of baseline ALT value Clarifications on the definition of 
baseline ALT value 
Section 7.1.2 Temporary 
Discontinuation Conditions updated for temporary 
discontinuation Temporary intervention discontinuation 
may be considered by [CONTACT_125501] a regional or national emergency declared by a 
governmental agency; The treatment 
with systemic corticosteroids in case of 
asthma exacerbation has been added 
Section 8.1 Efficacy 
Assessments  Updates based on the changes added in the 
SoA  Clarifications on the study procedures 
(HRCT scan, FeNO, FOT, spi[INVESTIGATOR_038]) according to SoA 
Section 8.[ADDRESS_141064] of AESI based on the new 
Investigator’s Brochure; updated 
definition of overdose with NIMP 
Section 8.3.5 Pregnancy Clarified instructions r elated to pregnancy 
reporting Clarification 
Section 8.4 Treatment of 
Overdose Clarifications on the instructions in case of IMP 
overdose Clarifications on the instructions 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page 109Section # and Name [CONTACT_19523] 8.10 Use of Data for 
Future Research Added new section for provisions and 
procedures followed in case of participant data 
use for future research Clarifications related to participant data 
used for future research 
Section 9.4.2 Safety analyses Added definition of TE period Clarification 
Section 10.1.1 Regulatory and 
Ethical Considerations Added GDPR to be followed 
Updated procedure to be followed for 
substantial protocol amendments 
Updated the Investigator’s responsibility Clarification 
Section 10.1.[ADDRESS_141065] of recruitment, and 
text Clarification 
Section 10.3 Appendix 3: 
Adverse Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow-Up, and 
Reporting Added subsection - definition of unsolicited and 
solicited AE, and text Clarification 
Section 10.4 Appendix 4: 
Contraceptive Guidance and 
Collection of Pregnancy 
Information Updated definition of WOCBP and WONCBP, 
and Contraception Guidance Updated contraceptive guidance   
Section 10.5 Appendix 5: Liver 
and Other Safety: Suggested 
Actions and Follow-Up 
Assessments Updated algorithm chart for increase in ALT Updated algorithm  
Section 10.8. Appendix 8: Country specific requirements Majority of age added for Taiwan Country specific requirement for Taiwan 
Section 10.9 Appendix 9: 
Contingency Measures for a 
Regional or National Emergency 
that is Declared by a 
Governmental Agency Summary of contingency measures for regional 
or national emergency declared by a governmental agency New appendix with the summary of the 
contingency measures 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page [ZIP_CODE].12.2 Amended protocol 01 (12 March 2020)
This amended protocol 01 is considered to be substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the Eu ropean Parliament and the Council of the 
European Union.
OVERALL RATIONALE FOR THE AMENDMENT
The main reason for the amendment is to meet requirements for Regulatory Agency.
Protocol amendment summary of changes table
Section # and Name [CONTACT_23688]
1.3 Schedule of activity 
5.2 Exclusion criteria 
10.2 Appendix 2: Clinical laboratory tests Addition of an exclusion criterion E07 related to 
tuberculosis and tuberculosis testing. 
Addition of tuberculosis testing and related 
footnote q. 
Table 8: Addition of tuberculosis testing As per Regulatory Agency review, 
patient with tuberculosis should not be 
included in the study. 
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page [ZIP_CODE] REFERENCES
1. Global Initiative for Asthma. Global Stratergy for Asthma Management and Prevention 
(GINA). 2019.
2. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 
2017;377(10):965-76.
3. Spahn JD, Malka J, Szefler SJ. Current applicati on of exhaled nitric oxide in clinical practice. 
J Allergy Clin Immunol. 2016;138(5):1296-8.
4. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel 
component of subepi[INVESTIGATOR_125414]-4 and IL-13
signals. J Allergy Clin Immunol. 2006;118(1):98-104.
5. Gandhi NA, Bennett BL, Graham NM, Pi[INVESTIGATOR_125415] G, Stahl N, Yancopoulos GD. Targeting key 
proximal drivers of type 2 inflammation in  disease. Nat Rev Drug Discov. 2016;15(1):35-50.
6. Boulet LP, Boulay MÈ, Dérival JL, Milot J, Lepage J, Bilodeau L, et al. Asthma-COPD 
Overlap Phenotypes and Smoking: Comparat ive features of asthma in smoking or non-
smoking patients with an incomplete reversibility of airway obstruction. COPD. 2018;15(2):130-8.
7. Sumi Y, Hamid Q. Airway Remodeling in Asthma. Allergol Int. 2007;56(4):341-8.8. Vos W, De Backer J, Poli G, De Volder A, Ghys L, Van Holsbeke C, et al. Novel functional 
imaging of changes in small airways of patients treated with extrafine 
beclomethasone/formoterol. Respi[INVESTIGATOR_1516]. 2013;86(5):393-401.
9. Vos W, Hajian B, De Backer J, Van Holsbe ke C, Vinchurkar S, Claes R, et al. Functional 
respi[INVESTIGATOR_125416]/LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2016;11:263-71.
10. De Backer J, Van Holsbeke C, Vos W, Vinchurka r S, Dorinsky P, Rebello J, et al. Assessment 
of lung deposition and analysis of the effect of fluticasone / salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in  stable persistent asthma patients using 
functional respi[INVESTIGATOR_125304]. Expert Rev Respir Med. 2016;10(8):927-33.
11. De Backer W, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Hufkens A, et al. The effect 
of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.Eur Respir J. 
2014;44(2):527-9.
12. Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrative stress in refractory asthma. J Allergy 
Clin Immunol. 2008;121(2):355-60.
13. Voraphani N, Gladwin MT, Contreras AU, Kaminski N, Tedrow JR, Milosevic J, et al. An 
airway epi[INVESTIGATOR_125417] –DUOX2 –thyroid peroxidase metabolome drives Th1/Th2 nitrative 
stress in human severe asthma . Mucosal immunol. 2014;7(5):1175-85.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141066]. 2018;6(6):1982-1988.e1. doi:10.1016/j.jaip.2018.03.004
15. Coumou H, Westerhof GA, de Nijs SB, Zwinderman AH, Bel EH. Predictors of accelerated 
decline in lung function in adult-onset asthma. Eur Respir J. 2018;51(2):1701785. doi:10.1183/13993003.[ZIP_CODE]
16. Sears MR. Lung function decline in asthma. Eur Respir J. 2007;30(3):411-413.
doi:10.1183/09031936.[ADDRESS_141067] corticosteroid re sponsiveness and reduce 
asthma exacerbation rates. Respir Med. 2013;107(7):943-952.
doi:10.1016/j.rmed.2013.02.018
18. Matsunaga K, Hirano T, Oka A, Ito K, Edakuni N. Persistently high exhaled nitric oxide and 
loss of lung function in controlled asthma. Allergol Int Off J Jpn Soc Allergol. 2016;65(3):266-271. doi:10.1016/j.alit.2015.12.006
19. van Veen IH, ten Brinke A, Sterk PJ, et al. Ex haled nitric oxide predicts lung function decline 
in difficult-to-treat asthma. Eur Respir J. 2008;32(2):344-349.doi:10.1183/09031936.00135907
20. Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO 
measurement in respi[INVESTIGATOR_3748]. Respir Med. 2014;108(6):830-841.doi:10.1016/j.rmed.2014.02.005
21. Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, et al. 
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): 
baseline data from a prospective cohort study. Lancet Respir Med. 2019;7(5):402-16.
22. Castro M, Corren J, Pavord ID, Maspero J, Wenz el S, Rabe KF, et al. dupi[INVESTIGATOR_125418]-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486-96.
23. Rabe KF, Nair P, Brusselle G, Maspero JF, Ca stro M, Sher L, et al. Efficacy and Safety of 
dupi[INVESTIGATOR_125419]-Dependent Se vere Asthma. N Engl J Med. 2018;378(26):2475-
85.
24. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official 
American Thoracic Society/European Respi[INVESTIGATOR_65201]: asthma control and 
exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J 
Respir Crit Care Med. 2009;180(1):59-99.
25. Burrowes KS, De Backer J, Smallwood R, Sterk PJ, Gut I, Wirix-Speetjens R, et al. Multi-
scale computational models of the airways to unravel the pathophysiological mechanisms in 
asthma and chronic obstructi ve pulmonary disease (AirPROM). Interface Focus. 
2013;3(2):20120057.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: [ADDRESS_141068] Pulmon 
Dis. 2011;6:637-46.
27. De Backer J, Vos W, Van Holsbeke C, Vinchurk ar S, Claes R, Parizel PM, et al. Effect of 
high-dose N-acetylcysteine on airway geometr y, inflammation, and oxidative stress in COPD 
patients. Int J Chron Obstruct Pulmon Dis. 2013;8:569-79.
28. De Backer J, Vos W, Vinchurkar S, Van Holsbeke C, Poli G, Claes R, et al. The effects of 
extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respi[INVESTIGATOR_125304]. J 
Aerosol Med Pulm Drug Deliv. 2015;28(2):88-99.
29. Hajian B, De Backer J, Sneyers C, Ferreira F, Barboza KC, Leemans G, et al. 
Pathophysiological mechanism of long-term noninvasive ventilation in stable hypercapnic patients with COPD using functional respi[INVESTIGATOR_125420]. Int J Chron Obstruct Pulmon Dis. 
2017;12:2197-205.
30. Biological Effects of Ionizing Radiation (BEIR) series - BEIR V.National Academy of 
Sciences. 1990. 
31. The 2007 Recommendations of the Internati onal Commission on Radiological Protection. 
ICRP Publication 103. Ann ICRP. 2007;37(2-4):1-332.
32. United Nations Scientific Committee on the Effects of Atomic Radiation. Summary of low-
dose radiation effects on health. UNSCEAR Website. 2010.
33. Araoz PA, Haramati LB, Mayo JR, Barbosa EJ Jr, Rybicki FJ, Colletti PM. Panel discussion: 
pulmonary embolism imaging and outcomes. AJR Am J Roentgenol. 2012;198(6):1313-9.
34. Ivanov VK1, Kashcheev VV, Chekin SY, Menyaylo AN, Pryakhin EA, Tsyb AF, et al. 
Estimating the lifetime risk of cancer associated with multiple CT scans. J Radiol Prot. 2014;34(4):825-41.
35. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupi[INVESTIGATOR_125421]. N Engl J Med. 2013;368(26):2455-66.
36. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task 
Force. Standardisation of spi[INVESTIGATOR_038]. Eur Respir J. 2005;26(2):319-38.
37. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B et al. Dup ilumab eﬃcacy and 
safety in adults with uncontrolled persistent  asthma despi[INVESTIGATOR_125422]-to-high-dose 
inhaled corticosteroids plus a long- acting β2 agonist: a randomised double -blind placebo-
controlled pi[INVESTIGATOR_30338] 2b dose-rang ing trial. Lancet. 2016;388([ZIP_CODE]):31-44.
38. Usmani OS, Singh D, Spi[INVESTIGATOR_125423] M, Bizzi A3, Barnes PJ. The prevalence of small airways 
disease in adult asthma: A systematic li terature review. Respir Med. 2016;116:19-27.
99&/,1
Amended Clinical Trial Protocol 03
SAR231893-LPS1583413-Apr-2023
Version number: 1
Property of the [COMPANY_011] group - strictly confidential Page [ZIP_CODE]. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, et al. Inflammation of 
small airways in asthma. J Allergy Clin Immunol. 1997;100(1):44-51.
40. Hyde DM, Hamid Q, Irvin CG. Anatomy, pathology, and physiology of the tracheobronchial 
tree: emphasis on the distal airways. J Allergy Clin Immunol. 2009;124([ADDRESS_141069]):S72-7.
41. Foy BH, Soares M, Bordas R, Richardson M, Bel Al, Singapuri A, et al. Lung Computational 
Models and the Role of the Small Airways in Asthma. Am J Respir Crit Care Med. 2019;200(8):982-91.
99&/,1
6LJQDWXUH3DJHIRU99&/,1Y
OSVDPHQGHGSURWRFRO
$SSURYH	H6LJQ
$SSURYH	H6LJQ
99&/,1